- Open Access
Redox mechanisms in hepatic chronic wound healing and fibrogenesis
© Novo et al; licensee BioMed Central Ltd. 2008
Received: 28 February 2008
Accepted: 13 October 2008
Published: 13 October 2008
Reactive oxygen species (ROS) generated within cells or, more generally, in a tissue environment, may easily turn into a source of cell and tissue injury. Aerobic organisms have developed evolutionarily conserved mechanisms and strategies to carefully control the generation of ROS and other oxidative stress-related radical or non-radical reactive intermediates (that is, to maintain redox homeostasis), as well as to 'make use' of these molecules under physiological conditions as tools to modulate signal transduction, gene expression and cellular functional responses (that is, redox signalling). However, a derangement in redox homeostasis, resulting in sustained levels of oxidative stress and related mediators, can play a significant role in the pathogenesis of major human diseases characterized by chronic inflammation, chronic activation of wound healing and tissue fibrogenesis. This review has been designed to first offer a critical introduction to current knowledge in the field of redox research in order to introduce readers to the complexity of redox signalling and redox homeostasis. This will include ready-to-use key information and concepts on ROS, free radicals and oxidative stress-related reactive intermediates and reactions, sources of ROS in mammalian cells and tissues, antioxidant defences, redox sensors and, more generally, the major principles of redox signalling and redox-dependent transcriptional regulation of mammalian cells. This information will serve as a basis of knowledge to introduce the role of ROS and other oxidative stress-related intermediates in contributing to essential events, such as the induction of cell death, the perpetuation of chronic inflammatory responses, fibrogenesis and much more, with a major focus on hepatic chronic wound healing and liver fibrogenesis.
From oxidative stress to redox homeostasis and redox signalling
At present, redox research is at the forefront of biomedical research in view of the expanding knowledge on the roles that increased and/or sustained levels of oxidative stress and related mediators have been described to play in major human diseases, including atherosclerosis, diabetes and cardiovascular diseases [14, 24–29], cancer [30, 31], neurodegenerative disorders [32–34], chronic liver [35–38] and lung diseases [39–41], to name just a few. Most of the conditions in which the role of oxidative stress and related mediators has been characterized belong to what one may define as chronic inflammatory/fibrogenic diseases, often involving chronic activation of wound healing.
About this review
This review has been designed as an attempt to offer a comprehensive, but not hyper-specialized, critical introduction to current knowledge in the field in order to introduce readers to the fascinating complexity of redox signalling and redox homeostasis regulation, with a major focus on chronic wound healing and liver fibrogenesis. This review will then offer a sequence of ready-to-use key information and concepts on major types of ROS, free radicals and oxidative stress-related reactive intermediates operating in living organisms, their sources in mammalian cells and tissues, and antioxidant defences. Along these lines, this review will not intentionally deal with all the details but, whenever possible, the interested reader will find indications for highly recommended and more detailed and specialized reviews and articles on specific topics.
ROS, free radical and non-radical reactive intermediates in biological materials
Reactive oxygen species
The superoxide anion O2•-
O2•- is the result of univalent reduction of triplet state molecular oxygen; its intracellular generation can primarily occur non-enzymatically by the intervention of redox components such as the semi-ubiquinone compound of the mitochondrial electron transport chain [8, 42] or through the intervention of enzymes like NADPH-oxidase (NOX) [43, 44], xanthine-oxidase and others (Figure 2; and see below) or in auto-oxidation reactions [7, 8, 42]. Major features of O2•- include: it is a relatively unreactive intermediate, being able to act at best as a mild reactant in physiological conditions and, indeed, only the interaction with nitric oxide (NO) to give peroxynitrite is able to transform superoxide into a very reactive intermediate; in living tissue, O2•- can be converted into H2O2 enzymatically by superoxide-dismutase (SOD) isoforms , or non-enzymically ; and it has a rather poor ability to cross biological membranes .
H2O2 represents a two-electron reduction state of molecular oxygen and originates mainly from enzymatic dismutation catalysed by superoxide dismutase (SOD) isoforms. H2O2 can also originate from non-enzymic dismutation of O2•- as well as from direct reduction of O2[8, 42]. Major features of H2O2 include: it can easily diffuse across biological membranes; it is a non-radical potent oxidizing agent; in aqueous solutions it can oxidize or reduce several inorganic ions [42, 45]; it can usually be removed by either catalase or glutathione peroxidase; it can give rise to the very reactive and damaging •OH when interacting with O2•- (Figure 1; Haber-Weiss reaction), or in the presence of divalent metal ions like iron and copper – when Fe2+ is present, the latter reaction is also defined as Fenton's reaction (or Fe2+-catalysed Haber-Weiss reaction) ; and myeloperoxidase of phagocytic cells use it to form hypochlorite (HOCl), a highly reactive compound able to oxidize thiol groups, amino groups and methionine in proteins.
OH is a three-electron reduction state of O2 formed during Haber-Weiss or Fenton reactions or by decomposition of peroxynitrite. OH has a very short half-life (10-9 s) and high reactivity. As such, in biological systems it does not diffuse from the site of generation and can rapidly damage any surrounding macromolecules, including: amino acids, potentially leading to protein inactivation/denaturation; carbohydrates, with degradation; lipids, leading to lipid peroxidation; and nucleic acids, leading, for example, to the formation of adducts with deoxyguanidine (8-OH-dG adducts, a reliable marker of ROS-dependent damage to DNA) and, potentially, to mutations.
Major reactions of ROS and other related free radicals
Figure 1 offers a summary of most relevant reactions leading to the generation of ROS or to their transformation into other reactive intermediates or inactive molecules. Reactions 1 to 12 have been already described, so we mention here only reactions 13 to 16. Reaction 13 is a 'starting' reaction, leading to the generation of an organic radical, R•, as a consequence of the interaction of •OH with an organic carbon-hydrogen bond. Peroxides, peroxyl-radicals as well as alkoxyl-radicals (reactions 14 to 16) can be generated during on-going oxidative stress as, for example, during lipid peroxidation.
Intracellular sources of ROS
In living cells ROS can be generated by several sources, but without any doubt the most relevant are those described in Figure 2.
Approximately 1–5% of electrons 'flowing' through the electron transport chain can be diverted to form O2•- at the levels of complex I (NADH/ubiquinone oxidoreductase) and complex III (ubiquinol/cytochrome c oxidoreductase). O2•- is then usually converted by mitochondrial SOD into H2O2, which can cross mitochondrial membranes to reach the cytoplasm [8, 42].
NOX is present in both professional phagocytic cells (macrophages, neutrophils and eosinophils) and non-phagocytic cells and plays a crucial role in different diseases [43, 44, 46], including chronic liver diseases (CLDs) [47, 48]. The classic phagocytic NOX is formed by the two membrane bound components p22phox and gp91phox/Nox2 (comprising the flavocytochrome b558) and four cytosolic components (p40 phox, p47phox, p67phox and the GTPase Rac1/2), which, following stimulation of phagocytic cells, are recruited to the plasma membrane where they interact with Cyt b558, leading to increased activity and then ROS generation. The NOX of non-phagocytic cells is similar in structure and function, with gp91phox/Nox2 being replaced by another member of the same family of proteins (usually by Nox2 homologues Nox1, Nox3, Nox4, Nox5 or Duox1/2). The main difference, relevant for redox signalling, is that non-phagocytic NOX is constitutively active, producing a very low level of ROS and increasing both its activity and ROS generation in response to a number of factors and conditions.
5-Lipoxygenase (5-LOX) is a mixed function oxidase involved in the synthesis of leukotrienes from arachidonic acid in response to essentially the same stimuli that are able to stimulate NOX, particularly growth factors and cytokines. The latter mediators lead to membrane ruffling and the generation of superoxide, and then H2O2, through the intervention of the small GTPase Rac1 and a SOD isoform [14–18, 49].
ROS can also be generated enzymatically in many subcellular compartments by several oxidases, peroxidases, and mono- and di-oxygenases as well as by isoforms of the cytochrome P450 superfamily. Here it seems relevant to mention xanthine oxidase [42, 50], nitric oxide synthase , cyclooxygenase [42, 52] and other NAD(P)H dependent oxido-reductases, which are all able to generate primarily O2•-. Similarly, peroxisomal oxidases  (glycolate oxidases, D-amino oxidases, ureate oxidases, fatty acid-CoA oxidases and L-α-hydroxyacid oxidases) can generate H2O2 when metabolizing various substrates. Also, lysyl oxidase , the enzyme catalysing the formation of the aldehyde precursors of cross-links in collagen and elastin, can give rise to H2O2.
The process of lipid peroxidation and the generation of non-radical intermediates
Nitric oxide and reactive nitrogen species
NO exerts physiological effects by controlling vascular tone, cell adhesion, vascular permeability and platelet adhesion [12, 13, 15, 60]. It also exerts several potentially toxic effects, although many of these are more likely mediated by oxidation products included in the definition 'reactive nitrogen species' (RNS). In particular, NO is able to rapidly react with O2•- to form the much more powerful oxidant peroxynitrite (ONOO-). Indeed, neither O2•- nor NO are particularly toxic in vivo because of efficient systems able to minimize their accumulation [61, 62]: O2•- is removed by SOD isoforms whereas NO is removed as a consequence of its rapid diffusion through tissues . Under pro-inflammatory conditions, simultaneous production of O2•- and NO can be strongly activated and significant amounts of ONOO- are generated, which may cause significant injury to different cellular structures.
How ROS and other oxidative stress-related reactive intermediates interact with biological macromolecules
ROS, NO, HAKS and other free-radical or non-radical reactive intermediates may interact with relevant biological macromolecules [7–9, 14, 15, 19, 21, 58], events that can easily lead to cytotoxic/damaging consequences or contribute to redox regulation and signalling.
ROS and other pro-oxidants
ROS and other pro-oxidants can interact with virtually any macromolecule of biological interest. Their interaction with DNA can lead to oxidative damage, strand breaks and the formation of adducts (such as 8-hydroxy-deoxyguanidine (8-OH-dG)). By interacting with polyunsaturated fatty acids in membrane phospholipids, ROS and reactive pro-oxidants can elicit peroxidation of lipids and their subsequent degradation and fragmentation. When interacting with proteins, ROS may lead to: (a) oxidation of critical amino acid residues, for example, the thiol group of cysteine; (b) formation of intra-molecular disulfide bonds (-S-S-); (c) thiol/disulfide changes leading to either formation or disruption of inter-molecular disulfide bonds between homo- or hetero-dimers; (d) formation of di-tyrosine and protein cross-linking; and (e) iron and copper metal ions can lead to the formation of OH radicals in a Fenton reaction – this can extensively damage target proteins, leading to their ubiquitination and proteasomal degradation. Reactions (a-c) can either lead to functional inactivation of the target protein or (c) convert a protein between its active and inactive states. Reactions (d) and (e) can lead to the formation of new antigens that the immune system may recognize as non-self.
Nitric oxide and reactive nitrogen species
RNS such as ONOO-  can easily lead to oxidation and formation of strand breaks when reacting with nucleic acids or to lipid peroxidation when interacting with membrane lipids. Again, RNS may simply lead to oxidative modification of proteins or to more selective reactions by nitrosation or nitration (Figure 5).
HNE, an aldehydic end product of lipid peroxidation, can exert both cytotoxicity as well as signalling modulation by forming Michael type adducts on lysine, cysteine or histidine residues [19–23]. HNE and other HAKs can also interact with nucleic acids, leading to formation of DNA adducts or even to strand breaks and genotoxicity. HNE may also operate by eliciting intracellular generation of ROS when interacting with mitochondria .
Protection from ROS and oxidants
The following categories of naturally occurring components may be defined.
This group of antioxidant enzymes includes 'major' enzymes such as catalase, glutathione peroxidase (GPX) isoforms and SOD isoforms. Catalase and GPX isoforms are responsible for the removal of H2O2 as well as other organic hydroperoxides, whereas SOD isoforms operate by transforming O2•- into H2O2 (Figure 7).
Protection by small molecules
Small molecules involved in protection from ROS and oxidants include ascorbic acid, reduced glutathione (GSH) and uric acid. Ascorbic acid (vitamin C) is a cofactor for several enzymes that has the ability to act as an electron donor and then as a reducing agent; ascorbate can also scavenge (that is, interact directly with) •OH but one has to briefly mention that, depending on the overall concentration, ascorbate may become deleterious by reducing Fe3+ to Fe2+ and, in the presence of H2O2, lead to the generation of significant amounts of •OH. GSH is a hydro soluble tripeptide acting as a substrate for H2O2-removing enzymes such as GPX and dehydroascorbate-reductase as well as a scavenger of •OH (leading to the thiyl radical GS•, which is not harmless) or as a thiol in regenerating the oxidized -SH groups of proteins; Figure 6 also shows the essential reaction of GSSG reductase, which recovers GSH. Uric acid, present in blood plasma, has been reported to scavenge singlet oxygen, •OH and peroxyl radicals.
Protection by sequestration of metal ions
Transition metal ions like iron and copper can exacerbate ROS generation. Ferritin, transferrin, ceruloplasmin, metallothionein and lactoferrin can thus be seen not only as relevant for their respective role in metal homeostasis but also as molecules that, by 'sequestering' redox active metal ions, may prevent ROS production via the Fenton reaction.
Thioredoxin and glutaredoxin systems
Thioredoxins (Trxs, including Trx-1 and Trx-2) [65, 66] are 12 kDa proteins with a catalytic site containing two cysteine residues that can be oxidized reversibly to form disulfide bridges. Trxs undergo NADPH-dependent reduction by Trx-reductase and, in turn, they can reduce oxidized cysteine groups on proteins. Through this intramolecular disulfide-thiol exchange, Trxs can act as hydrogen donors, contributing to the control of redox state. Trxs (mainly Trx-1) may supply reducing equivalents to a number of Trx peroxidases (peroxiredoxins) and also play a role in redox signalling by modulating kinases or transcription factors by forming heterodimers with them.
Glutaredoxins (Glrxs, the cytosolic Glrx-1 isoform and Glrx-2, the latter existing as both mitochondrial and nuclear isoforms)  also belong to the Trx superfamily of thiol/disulfide exchange proteins and act as reductants of protein-SG mixed disulfides. Similar to what was described for the Trx system, Glrxs have a role in redox regulation and the Glrx system is composed of Glrx isoforms, GSH reductase, GSH and NADPH.
Protection from lipid peroxidation: natural and synthetic antioxidants
According to Halliwell and Gutteridge  "an antioxidant is any substance that, when present at low concentrations compared to those of an oxidizable substrate, is able to significantly delay or inhibit oxidation of that substrate." Of course, this generic definition also includes primary antioxidants (free radical scavengers able to interact directly with and/or to block the initiating free-radical, such as mannitol) and synthetic molecules able to bind metal ions (for example, desferrioxamine). However, several authors, when using the word 'antioxidant', have in mind the so-called 'chain breaking' or 'secondary antioxidants', with α-tocopherol (vitamin E) being the naturally occurring prototype. These natural or synthetic molecules have a chemical structure (Figure 8) able to intercept radical intermediates produced during on-going lipid peroxidation, such as peroxyl or alkoxyl radicals, thus preventing (that is, 'breaking') the perpetuation of hydrogen abstraction in the chain reaction. Figure 6 offers an overview of the reactions involving α-tocopherol, including its re-cycling based on the involvement of GSH and ascorbate.
A number of additional and useful concepts regarding antioxidants (whether enzymic or not) should be considered: antioxidants binding metal ions are not usually consumed during the course of reaction; antioxidants able to decompose peroxides may be consumed or not, depending on their nature (for example, as enzymes GPXs are not consumed); chain breaking – as well as primary – antioxidants are usually consumed during on-going oxidative stress; many antioxidants have multiple mechanisms of action; some antioxidants (tocopherols, ubiquinol, carotenoids and flavonoids) will exert their effects in a lipid phase (that is, at the level of biological membranes) whereas others will do so in an aqueous phase (ascorbate, urate, GSH and other thiols).
Redox homeostasis, redox signalling, redox sensors and redox-dependent transcriptional regulation in mammalian cells: the good, the bad and the ugly
Redox signalling is a definition that can be used to indicate any physiological or pathophysiological condition in which a process can be regulated or modulated by a signal that is delivered through redox chemistry [14–18]. When significant levels of ROS are generated in a biological system (that is, altering redox homeostasis), 'redox signalling' then represents the response or part of the response designed to 'reset' the original state of equilibrium. As in any complex system reacting to the presence of defined reactants, single cells and multicellular organisms have developed highly specific redox sensors and mechanisms that form the basis of oxidant scavenging and ROS signalling systems.
Principles of redox homeostasis
Physiological conditions or unstimulated cells
Under physiological conditions, relatively low amounts (steady-state levels) of ROS, free radicals and other reactive intermediates are produced as a result of a dynamic balance between the rate of their generation and removal. Redox homeostasis is primarily controlled by catalase, Trxs, SODs and GPXs, as well as by naturally occurring antioxidants like GSH, vitamin E, β-carotene, ascorbate, urate, and many others. However, enzymes and natural antioxidants that are highly specific are present at relatively low concentrations; the antioxidant arm of the so-called oxidant/antioxidant balance is significantly implemented by less specific or efficient, but much more abundant, actors that are represented by amino acids, peptides and proteins [14–18, 42, 65, 66]. Indeed, almost all amino acids may serve as molecular targets for pro-oxidants (cysteine, tyrosine, tryptophan and histidine being the most sensitive to oxidants) and the intracellular concentrations of free amino acids reach levels as high as 10-1 M. Oxidized proteins may offer an additional contribution: oxidative attack on proteins can lead to inactivation, fragmentation, aggregation of fragments and/or increased susceptibility to proteolysis. Proteolytic degradation of oxidized proteins is mainly due to 20S proteasome and it has been proposed that oxidatively fragmented and/or misfolded proteins have an increased ROS scavenging activity than normal, non-oxidized proteins [67–69]. In practical terms, cells in which very low levels of ROS are generated (a baseline-like or steady state condition, as in Figure 9a) do not suffer a significant imbalance in pro-oxidants versus antioxidant defences and do not respond by means of a redox signalling.
Cells exposed to an 'acute' and/or 'isolated' versus chronic generation of ROS
Whenever redox homeostasis is significantly disturbed – by an increase in ROS generation, by a decrease in one or more antioxidants or by a change in the thiol/disulfide redox state – redox signalling can be elicited [14–18]. Three different scenarios, depending on the absolute intracellular levels of ROS and other reactive species or the temporal length of the alteration, may be envisaged (Figure 9b).
In the first scenario, the increase in ROS is relatively low and transient (Figure 9b1). In these conditions, the shift in redox balance will be limited and redox signalling will operate through redox-sensitive signalling pathways and transcription factors [14–18] in order to up-regulate genes encoding products that will reset redox homeostasis (enzymes, Trxs and Glrxs, the cystine transport system to sustain the production of GSH, and so on).
In the other two scenarios, oxidative stress is more severe (Figure 9b2 and 9b3). During acute tissue injury or in tissues undergoing chronic injury, levels of intracellular ROS and other reactive intermediates may be very high and/or persistently increased within cells. The 'oxidative stress response' may not be sufficient to contain disturbances and reset the original redox homeostasis. Depending on several factors (that is, the specific agent or condition involved, the overall severity of the injurious process, and so on) this may cause at least two scenarios. Levels of ROS or reactive intermediates may be high enough within the cells to significantly damage macromolecules or alter cellular structures and functions, eventually leading to irreversible injury and cell death (Figure 9b2). If levels of oxidative stress are significantly higher but are not able to induce irreversible cell damage, as may occur in conditions of chronic injury, cells and/or tissues may still reach an equilibrium or, as elegantly defined by Dröge , a 'quasi-stable state' (Figure 9b3). This definition implies a shift of the intracellular redox state to higher levels of ROS and a chronically deregulated state in which redox signalling can up-regulate patterns of gene expression and cell responses that are believed to significantly contribute and/or sustain the development of chronic diseases and even cancer progression [15, 70]. Of course, the scenario given in Figure 9b1–b3 is a didactic one and in a tissue undergoing chronic injury, inflammation and wound healing the three conditions are likely to coexist, with an overall scenario in which the development of the disease results from the sum of both ROS-dependent damaging effects and changes in gene expression.
Redox sensors and the basis of redox-dependent transcriptional regulation
At this point one should move beyond the simple concept of oxidant/antioxidant balance by introducing the more refined notion of redox sensors as well as the principles of redox-dependent regulation of transcription. The key messages in this area (for more details see [18, 71]) can be summarized as follows.
The definition of 'redox sensors'
A redox sensor is a specialized redox-sensitive protein that is able to 'sense' or 'measure' intracellular levels of ROS by a redox-based mechanism affecting one or more residues/domains within its three-dimensional structure, and to transform the redox change into a specific setting for antioxidant activity-related transcription and, particularly for mammalian cells, much more.
Redox sensors in prokaryotic cells and yeast
Redox sensors in higher eukaryotes
The meaning of redox sensors and redox signalling in higher eukaryotes
In mammalian cells, ROS-specific responses such as those regulated by p53, activator protein (AP)-1, nuclear factor (NF)-κB, c-Myc, FOXO and other factors can be seen as part of long-term differentiation programmes that integrate ROS protection and multiple metabolic/adaptative responses. Higher eukaryotes have developed strategies that, by diverting the original defensive design of redox signalling, use intracellular ROS produced within cells to modulate several signalling pathways, such as those downstream of growth factor receptors. Redox changes and ROS signals may potentially simultaneously affect different signalling pathways, modulating main metabolic or adaptative responses of cells and playing a strategic role in several physiological or pathophysiological conditions, including many chronic diseases of clinical relevance.
Chronic injury and liver fibrogenesis: the tissue, cellular and molecular scenario involving liver parenchyma as a paradigm to introduce the role of ROS and redox signalling
Patterns of fibrosis progression in CLDs
Fibrosclerotic progression follows distinct patterns that are intrinsically related to the aetiological cause of the CLD and the topographic site of tissue injury, as well as to the predominant pro-fibrogenic mechanism and the involvement of populations of pro-fibrogenic myofibroblast-like cells of different origin (MFs). Four main patterns of fibrosis have been identified and are described in detail in Figure 14.
Myofibroblast-like cells as pro-fibrogenic effectors in CLDs
Major events, cells and mechanisms regulating liver fibrogenesis in CLDs
Several relevant events for fibrosclerotic progression of CLDs may be considered relatively independent of the specific aetiology, as detailed in Figure 13; in these conditions of persisting tissue injury, ROS and other related mediators, released by damaged cells or activated inflammatory cells, are likely to play a relevant role. Along these lines, it should be noted that, in chronic diseases, both necrotic and apoptotic, as well as apoptosis-like, forms of cell death have been reported to occur and have been detected in the same tissue section [80, 95, 96] and that hepatocyte apoptosis represents an effective pro-fibrogenic stimulus [97, 98].
ROS and intracellular signalling cascades: redox sensitive molecular targets in signalling pathways likely to be involved in chronic wound healing
Signal transduction elicited by interaction of peptide factors (growth factors, cytokines, chemokines as well as other ligands) with their respective receptors can be enhanced or modulated by intracellular ROS generation. Indeed, peptide ligands also trigger activation of NOX but the positive feedback on signal transduction can also be elicited whatever the source of ROS, including ROS produced by mitochondria and other intracellular sources or entering the cell from the extracellular environment. The latter can include H2O2, which has a rather long half-life, a relatively low reactivity and an intrinsic ability to cross biological membranes. The literature concerning redox sensitive signalling pathways is now impressive (for more details, see [14, 15, 17, 49]) and here we present the most established concepts that may have a major role in chronic wound healing.
ROS and receptor-mediated signalling pathways
ROS can enhance signalling pathways by inhibiting protein tyrosine phosphatases
Protein tyrosine phosphatases (PTPs) can be considered as negative regulators of RTK-mediated signalling, switching off the activated receptor by means of dephosphorylation [49, 99–101]. However, ligand-induced activation of RTKs can lead (as for PDGF signalling; Figure 17) to phosphoinositide 3-kinase (PI3K)-mediated activation of Rac that, in turn, is able to switch on ROS generation by NOX [49, 99]. ROS such as H2O2 can act on a redox-sensitive cysteine residue with a low pKa in the active site of PTPs (a similar condition has been described also for p21Ras, AP-1, NF-κB and hypoxia-inducible factor (HIF)-1) by oxidizing the -SH group of the active PTP. Depending on ROS levels (Figure 17), this may result in reversible as well as irreversible inactivation of PTPs, reinforcing downstream RTK signalling for variable durations. This scheme has been described also for radiation, exposure to metals, alkylating agents and environmental oxidants, and conditions that may even activate RTKs in a ligand-independent manner – 'RTK trans-activation' . Changes in intracellular thiol/disulfide redox state may also affect the system since the relative, or time-limited, depletion of reducing agents may prevent reversion of oxidized/inactive PTPs to the reduced/active state.
ROS can activate protein kinases as well as MAPK cascades
Cytoplasm protein kinases can respond to very high levels (1 mM) of H2O2 by enhancing their activity, as shown in pioneeristic studies [14, 15]. Whether these high concentrations of ROS may be reached in a biological environment is still controversial. If one refers to more realistic studies, few molecular targets and pathways have been identified to be activated by mild oxidizing conditions or by mild shifts in the intracellular thiol/disulfide redox state, including signalling components of the Src family of protein tyrosine kinases (p59fyn and p56lck), JAK2, c-Jun amino-terminal kinases (JNKs), p38MAPK and, in some cells, ERK1/2. A peculiar mechanism is the one disclosed in studies designed to analyze ASK-1 (apoptosis signalling-regulating kinase 1) activation, which, in turn, leads to activation of MKK3/6, MKK4/MKK7 and then JNKs and p38MAPK, finally leading to phosphorylation of ATF-2, c-Jun and p53. Elegant studies have shown that ASK-1 is usually associated with a Trx protein that binds to the amino-terminal domain of ASK-1, inhibiting its kinase activity. If ROS induce Trx dimerization and dissociation from ASK-1, this is followed by multimerization of ASK-1, activation of its kinase activity and then of the downstream signalling, leading to activation of JNKs and p38MAPK [103, 104].
Another interesting example of redox sensitivity is that of the serine/threonine kinase protein kinase Cα (PKC-α) [14, 15]: this and other PKC isoforms are usually activated by diacylglycerol or phorbol esters, for which PKC has a binding site in an evolutionarily conserved cysteine-rich region. These PKC isoforms can be activated by ROS like H2O2 in a way that involves tyrosine phosphorylation in the catalytic domain. Interestingly, vitamin E has been described to inhibit the activity and translocation of PKC to the membrane and to be able to down-regulate some PKC-dependent responses (that is, proliferation) in target cells like smooth muscle cells; intriguingly, data on modulatory effects by vitamin E have been extended to other components of the signalling machinery, suggesting that only some of these effects may depend on the antioxidant activity of the vitamin .
ROS and oxidative stress can activate defined transcription factors
Several transcription factors can be considered as redox sensitive but the two best characterized examples are NF-κB and AP-1. NF-κB is a transcription factor shown to respond to oxidative stress  and it is known to be involved in inflammatory reactions, in the control of cell growth and the balance between survival and apoptosis  and, possibly, necrotic cell death  (see below). NF-κB, a definition that, in mammalian cells, includes c-Rel, RelA (p65), RelB, NF-κB1/p50 and NF-κB2/p52 proteins, which all recognise DNA sequences called κB sites [107, 109, 110], is also involved in maintaining mitochondrial integrity and in regulating antioxidant activity [107, 110]. The redox-dependence of NF-κB relies on different mechanisms of activation that, depending on the specific target cell, may involve either an atypical phosphorylation of the Tyr42 residue of IκBα by the kinase Syk (thus, independently of IκB kinase (IKK)) or a more conventional H2O2-dependent activation through the classic IKK-dependent pathway , the latter being activated also by HOCl, singlet oxygen and peroxynitrite.
Within the same scenario one can also easily include AP-1, a dimeric (homo- or heterodimer) transcription factor typically formed from c-Jun and c-Fos and involved in several physiological and pathophysiological processes. Activation of AP-1 occurs in the presence of low levels of ROS (mainly H2O2), IL-1, UV light, and γ-irradiation. Two mechanisms may lead to redox-dependent activation of AP-1: oxidative activation of JNKs that, in turn, phosphorylate Ser63 and Ser73 of the amino-terminal transactivation domain of c-Jun, a domain that is essential for functional activation ; and a mild shift in the redox state by different oxidants or ROS [14, 15].
A cautionary note has to be added: one should keep in mind that the DNA-binding activity of most transcription factors is redox sensitive in the opposite way. It has been shown that the binding of transcription factors to a DNA regulatory sequence requires reducing conditions because transcription factors must expose positively charged amino acid residues in their binding sites in order to be able to bind target DNA sequences (usually highly acidic and negatively charged). This introduces an apparent paradox: the binding site of a transcription factor presents redox-sensitive amino acids (cysteine, arginine) and, as is the case for NF-κB, oxidation of these critical residues may prevent its DNA-binding activity. This note is to underline that even in physiological conditions, the final response to redox changes relies on a delicate balance between pro-oxidant conditions needed to reinforce the signal and reducing conditions needed for the same signal (that is, the transcription factor) to be efficiently delivered in order to obtain the response. Pathophysiological conditions (Figures 9 and 19) can easily interfere with such a delicate balance by shifting redox homeostasis to a 'quasi-stable' but deregulated redox state.
ROS and oxidative stress in relation to CLD aetiology
In addition to the general mechanisms able to sustain increased generation of ROS and other reactive mediators that are common to all conditions of human and experimental CLDs (that is, cell injury and death, chronic hepatitis, responses to growth factors, cyto- and chemokines, and so on), one should also consider the intrinsic contribution of the specific aetiology of a CLD. This is relevant when the primary aetiology is represented by chronic ethanol consumption, a disturbance of iron homeostasis or metabolic imbalances like those occurring in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Clinical observations have clearly established that all these three very common conditions, as independent factors, may significantly affect and accelerate fibrogenic progression of any CLD towards cirrhosis.
Iron and its role in fibrogenic CLDs
Iron in its ferrous (Fe2+) or ferric (Fe3+) forms is critical for the life of all aerobic organisms, being included in haemoproteins like haemoglobin and myoglobin, metalloproteins, cytochromes and redox-dependent enzymes involved in oxygen and electron transport as well as in several other reactions, including oxygen sensing, NO sensing, DNA synthesis and transcriptional regulation. Major achievements in the understanding of hereditary hemocromatosis (HH) have disclosed in a detailed way [111, 112] crucial molecular and cellular mechanisms responsible for the control of iron homeostasis. Iron levels are carefully controlled in terms of adsorption, stores, plasma levels and transferrin saturation, whereas major physiological pathways for its excretion are lacking in higher organisms. The literature suggests that increased levels of hepatic iron (the liver being the most relevant site of storage) can significantly contribute to fibrogenic progression of a CLD.
If one comes back to the central point (that is, how iron may contribute to fibrogenesis and CLD progression), several hypothesis have been proposed in which the pro-oxidant role of the metal ion remains prominent. The following concepts may be relevant: first, increased oxidative stress and lipid peroxidation have been detected in association with all major conditions of hepatic iron overload [35, 113]; second, in animal models evidence suggests that antioxidant supplementation is able to significantly prevent both iron-dependent chronic liver injury and excess ECM deposition [35, 120, 121]; and third, iron overload may induce cytotoxicity that primarily depends on the ability to generate oxidative stress and operates by inducing mainly mitochondrial damage (including damage to mitochondrial DNA) and destabilization of lysosomal membranes [122–124].
Another concept should be recalled: intracellular levels of iron are usually carefully controlled (as in hepatocytes or macrophages) by means of iron binding to cytoplasmic Iron regulatory proteins (IRP-1 and IRP-2) and the expression of genes involved in iron homeostasis through the binding of IRPs to Iron responsive element (IRE) sequences, including those for transferrin receptor (TfR) and ferritin (Ft). An uncontrolled rise in intracellular iron may lead to the formation of a low molecular weight pool of iron potentially able to convert O2•- and H2O2 into highly reactive •OH radicals or ferryl ions. IRPs may indeed represent a target for ROS and RNS, possibly as part of a more general scheme designed to protect the intracellular environment from oxidative stress . IRP inactivation should, by down-regulating TfR expression and up-regulating Ft, decrease the intracellular labile iron pool, thus preventing amplification of iron-mediated oxidative damage. We do not know whether these regulatory mechanisms may be altered in CLDs, although it has been proposed that inactivation of IRP-2 (which is usually highly expressed in macrophages) by RNS may help to explain iron sequestration patterns of macrophages detected in tissues undergoing inflammation .
Copper is another transition metal acting as an excellent pro-oxidant catalyst that may contribute to enhance oxidative stress in Wilson's disease (WD), the human disease in which hepatic copper overload can occur. WD is an autosomal recessive disease caused by mutations in the gene encoding the copper-transporting P-type ATPase, ATP7B, required for copper biliary excretion [126, 127]. As for iron overload, copper overload has also been described to cause hepatic oxidative stress, leading to hepatocyte injury and subcellular damage to several structures , although other mechanisms, either oxidative or non-oxidative, may offer significant contributions [35, 36, 129].
Chronic ethanol consumption and metabolism: induction of oxidative stress and related events
Chronic ethanol consumption can lead to ALD, which encompasses a large spectrum of pathological liver changes, ranging from simple fatty liver with minimal injury to alcoholic steatohepatitis (ASH) and, in more advanced stages, fibrogenic progression to cirrhosis. Progression of ALD is now considered a multifactorial process involving nutritional, environmental and genetic factors , and ethanol consumption also represents one of the major host-related factors able to accelerate progression of fibrosis towards cirrhosis in chronic HCV patients [131, 132] and, possibly, in patients affected by CLDs with a different aetiology. The role of ROS and oxidative stress in the pathogenesis of ethanol-induced liver injury has been extensively investigated [133–136]. Here the following relevant concepts are recalled. First, experimental and clinical data indicate that oxidative stress and lipid peroxidation are involved, with antioxidants and free radical scavengers being able, at least in animal models, to afford prevention . Second, ethanol-related ROS can be produced by the mitochondria respiratory chain, ethanol metabolizing (and ethanol-inducible) cytochrome P450 2E1 (CYP2E1) in hepatocytes, but not in HSCs , and NOXs of activated Kupffer cells or infiltrating neutrophils [133–135]; NO produced by NO-synthase of Kupffer cells and other RNS has also been shown to contribute to ethanol-dependent hepatic injury [135, 136]. The CYP2E1 isoform can also lead to generation of the ethanol-derived hydroxyethyl radical. Third, ethanol-induced oxidative stress is likely to contribute to liver steatosis found in alcoholics  by causing an impairment in either mitochondrial lipid oxidation  or lipoprotein secretions, the latter being related to enhanced degradation of ApoB100  and/or oxidative alteration of lipoprotein glycosilation in Golgi apparatus . Fourth, CYP-2E1 generated ROS and formation of protein adducts by lipid peroxidation products may affect proteasomal degradation leading to cytoplasmic aggregates of cytokeratins 8 and 18, leading to the formation of Mallory's bodies . More features of ethanol-induced oxidative stress are presented below (see the sections 'Ethanol-related redox mechanisms leading to mitochondrial damage and hepatocyte apoptosis', 'Redox mechanisms and chronic inflammatory response in CLDs', 'Redox mechanisms in liver fibrogenesis: pro-fibrogenic cells as a functional target' and 'Redox mechanisms in immune reactions associated with CLDs: fuel for chronic inflammation and fibrogenic progression').
ROS and oxidative stress-related reactive intermediates in NAFLD and NASH: their generation and role in causing steatosis
The term NAFLD refers to a wide spectrum of disorders having in common hepatic steatosis as a hallmark but also encompassing NASH, advanced liver fibrosis and cirrhosis. NAFLD is actually recognized as a major cause of liver-related morbidity and mortality, with a very high prevalence in Europe, USA and, more generally, in western countries (reviewed in [142–145]).
Other mitochondrial dysfunctions occur in NASH patients, some possibly due to up-regulation of uncoupling protein-2 (UCP-2) or representing the consequence of an oxidative stress-dependent derangement of mitochondrial membranes and/or the respiratory chain that may result in an increased release of ROS from mitochondria. The role of UCP-2 is still controversial and has recently been critically reviewed .
Oxidative stress and related reactive intermediates may contribute, as proposed for ethanol, to the genesis of steatosis by negatively affecting secretion of lipoproteins (either by enhancing degradation of Apo-B100 or by affecting lipoprotein glycosylation in the Golgi apparatus) [135, 140] or even by interfering with the regulation of lipid synthesis by the sterol regulatory element binding protein 1 (SREBP-1) or the peroxisome proliferator-activated receptor α (PPAR- α) . Moreover, ROS have been proposed to contribute to insulin resistance (IR) itself: activation of stress-activated protein kinases by ROS can lead to impairment of the correct transduction of insulin-mediated signals through the induction of serine and threonine phosphorylation of IRS-1 (insulin receptor substrate-1) and the concomitant down-regulation of IRS-1 tyrosine phosphorylation [157, 158]. This has been confirmed by studies performed in hepatocytes overexpressing CYP2E1 .
Finally, the pivotal role of ROS in NAFLD progression has been shown by Xu et al. , who, in an elegant study (commentary in ), described the key role of the Nrf-1 gene, which is known to be involved in mediating activation of the oxidative stress-response. When using a mouse model of selective hepatic deletion of the Nrf-1 gene, the liver of these animals developed progressively all the characteristic features found in the progression of human NAFLD, including steatosis, apoptosis, necrosis, hepatitis, fibrosis and even liver cancer.
Chronic HCV infection and oxidative stress
The occurrence of oxidative stress is a common finding in human patients affected by chronic HCV infection (reviewed in ) and is likely to rely mostly on the actual conditions of persisting liver injury and chronic inflammation. However, experimental studies have proposed that HCV core protein may induce mitochondrial injury in hepatocytes, leading to increased generation of ROS [163, 164]. Mice overexpressing HCV core protein showed alterations of redox homeostasis in the absence of significant inflammation and were more susceptible to the hepatotoxin CCl4 . Moreover, overexpression of viral proteins in these transgenic mice was found to be associated with the development of steatosis and hepatocellular carcinoma, two common features of chronic HCV infection in humans .
Other researchers have provided similar evidence for the HCV non-structural protein 5A (NS5A), which has been shown to associate with the membranes of endoplasmic reticulum (ER) and increase generation of ROS and activation of NF-κB and STAT-3  as well as of JNKs and p38 MAPK . NS5A-mediated activation of NF-κB seems to operate through tyrosine phosphorylation of IkBα and its degradation by calpain protease . Thus, HCV by itself may contribute to elicit a state of oxidative and nitrosative stress in affected patients and the following major concepts, as recently reviewed , should be outlined. First, only some HCV-related proteins, such as NS5A, NS3 and HCV core protein, are likely to play roles in mediating redox perturbations, which can include increased generation of both ROS and RNS, iNOS and COX-2 (NS5A and C). Second, significant alterations of redox state may help to explain synergistic effects of HCV and alcohol on the progression of disease. Lastly, ROS and ethanol consumption may influence HCV replication and affect the outcome of interferon therapy.
Recently, another concept has been introduced by a study performed on transgenic mice expressing the HCV polyprotein: HCV-induced excess generation of ROS causes down-regulation of hepcidin synthesis through inhibition of the DNA binding activity of C/EBPα , an event able to increase iron transport from duodenum and iron release from macrophages, which lead potentially to iron overload and related consequences.
Chronic cholestatic diseases and oxidative stress
The pattern of fibrosis in diseases of the biliary tract is peculiar and involves either significant alterations in the interactions between cholangiocytes and mesenchymal cells as well as generation of ROS and occurrence of oxidative stress. In adults and children, chronic cholestasis is usually the consequence of cholangiopathies due to autoimmunity, infectious or toxic agents, ischemia or genetically transmitted defects. All these cholangiopathies share features such as cholestasis and cholangiocyte loss associated with cholangiocyte proliferation and a variable degree of portal and periportal inflammation and fibrosis [171, 172]; relevant is the 'cross-talk' between cholangiocytes, portal MFs and/or HSCs, first demonstrated for PDGF-BB and PDGF-β R , with cholangiocytes being able to secrete IL-6, TNF, IL-8 and MCP-1 as well as PDGF, ET-1, TGFβ2 and CTGF (reviewed in ).
Oxidative stress and lipid peroxidation have been detected in the most relevant clinical conditions, including primary biliary cirrhosis and the bile duct-ligation model in the rat [174–178], with antioxidant providing a significant degree of protection in animal models (reviewed in [35, 36]). Generation of ROS, induction of oxidative stress and lipid peroxidation may represent the consequences of activation of inflammatory cells, as in the bile duct ligation (BDL) model , but ROS generation may even follow a direct effect of hydrophobic and cytotoxic bile acids on hepatocyte's mitochondria, thus mediating hepatocyte necrotic cell death and/or apoptosis [128, 179–182]. Recently, it has been suggested that intracellular generation of ROS may also mediate cholangiocyte apoptosis found in primary biliary cirrhosis .
Oxidative stress and genetic polymorphisms
Genetic polymorphisms may have a significant role in fibrotic progression of CLDs, as suggested by the broad spectrum of manifestations or responses that individual patients offer to the same aetiological agent or condition. Bataller and coworkers  have delineated a list of candidate genes involved and, not surprisingly, most, if not all, of the 'suspected' polymorphisms concern factors or enzymes that are known to be directly or indirectly either redox-sensitive or involved in the generation of ROS or other relevant reactive intermediates. The actual list includes genes encoding cytochrome P450 isoform CYP2E1, alcohol-dehydrogenases (ADHs), and Mn-SOD, as well as a number of cytokines, including TGFβ1 and TNFα.
Redox mechanisms in the induction of cell death in CLDs: much more than a dose-dependent process
Oxidative stress as an event able to induce cell death
Persisting liver injury and hepatocyte loss are common in CLDs and oxidative stress is likely to play a relevant role in inducing both necrotic as well as apoptotic cell death [136, 184–187]. Severe oxidative stress, able to significantly damage any relevant biological macromolecule and cellular structure, is an obvious candidate to induce necrosis and may represent the outcome of severe inflammatory response following acute liver injury, with activated Kupffer cells, neutrophils or recruited mononuclear cells from peripheral blood being the 'effectors' of increased generation of reactive species. High levels of intracellular oxidative stress may also be reached within hepatocytes damaged by specific toxins (for example, CCl4 and acetaminophen) or aetiologies (for example, high levels of transition metal ions) or because of individual differences, including induction of peculiar cytochrome P450 isoforms (such as CYP2E1 in ASH/ALD or NASH), antioxidant status or even genetic polymorphisms.
In the scenario of a chronic inflammatory and fibrogenic disease, the first point to be discussed is the following: what do we mean, in terms of concentrations, by 'high levels of oxidative stress'? The literature offers the following considerations: reliable analytical (that is, quantitative) data on steady state concentrations of ROS as well as of other critical reactive intermediates are lacking for human liver of patients affected by a CLD; and the best data come from analyses performed on livers of animals undergoing experimental models of acute liver injury. In the liver of mice treated with acetaminophen, a model of severe and oxidative stress-dependent acute liver injury and failure, sophisticated techniques have detected a total concentration of approx 0.25 μM ROS, with H2O2 detected at levels of 0.15 μM ; in the CCl4 model of oxidative stress-related acute liver injury, intrahepatic levels of HNE reached maximal values around 10 μM .
Data on acute liver injury should imply that during CLDs tissue levels of ROS and other mediators are likely to be lower; this has been shown for HNE levels, which ranged from 1–3 μM in chronic CCl4 treatment and BDL (reviewed in [35, 36]). Although several researchers have the feeling that in some conditions (that is, the environment of biological membranes within the cell, the site of active inflammation, the concomitance of more 'pro-oxidant events') ROS may locally reach levels higher then those reported in , these data suggest caution when interpreting results obtained in vitro by exposing either suspensions of freshly isolated cells or cultured cells to unrealistic concentrations of ROS or HNE, such as in the range 0.1–1.0 mM. The problem of the 'steady state' concentration of reactive intermediates is not academic: reactive intermediates of oxidative stress can induce necrotic cell death, caspase-dependent apoptosis [184–186] or other intermediate forms, including apoptosis-like or necrosis-like cell death , even in the presence of the same pro-oxidant agent or condition [179–182, 190, 191]. This is relevant in the parenchymal chronic 'battlefield': whatever the aetiology of the CLD, signs of both necrosis and apoptosis can be found in the same section, in association with the other events of the chronic scenario (inflammation, fibrogenesis, angiogenesis, and so on) [185, 186]; moreover, apoptosis can indeed act in a pro-inflammatory and pro-fibrogenic way, thus sustaining progression of the CLD .
Some years ago, Kaplowitz  proposed that necrotic cell death may occur in cells exposed to very high levels of oxidative stress and be able to irreversibly damage mitochondria or to inactivate executioner caspases. This indeed may happen, as shown by in vitro experiments, in hepatocytes  or human HSC/MFs [189, 191] exposed to very high concentrations of HNE (50 μM or more). However, it is not really easy sometimes to identify which mode of cell death may predominate in different conditions of liver disease. Recently, Mahli and coworkers  have proposed that controversies about this specific feature may be solved by recognizing that apoptosis and necrosis frequently represent alternative outcomes of the same pathways leading to cell death. For example, even in conditions able to induce caspase-dependent apoptosis (activation of either intrinsic pathways or of death receptor-related pathways), severe mitochondrial changes with membrane depolarization and uncoupling of oxidative phosphorylation may result in ATP depletion and, thus, in the blocking of caspase activation and classic apoptosis.
In the next sections a number of concepts and mechanisms involved in ROS-dependent and 'aetiology-related' forms of hepatocyte death are outlined to possible serve as a paradigm to understand the extremely complex scenarios occurring in CLDs.
ROS and mitochondria in cell death
Alterations of mitochondria have a role in different types of either caspase-dependent or caspase-independent cell death  and are strictly associated with ROS. If mitochondrial integrity is deranged, this will be associated with the dissipation of the mitochondrial inner transmembrane potential (ΔΨm), leading to mitochondrial outer membrane permeabilization and release of pro-apoptotic proteins such as cytochrome c, Smac, Diablo and AIF, leading then to apoptosis. Increased permeabilization of the mitochondrial outer membrane can also lead to increased intracellular ROS generation as a consequence of damage to the mitochondrial electron transport chain. ROS may also increase permeabilization of mitochondrial outer membrane by altering thiol groups of ANT (Adenine nucleotide translocase) or VDAC (Voltage-dependent anion channel), the latter being required for superoxide anion efflux from mitochondria. The overall message then is quite simple: mitochondria can represent not only a source of ROS but also a target for their action in relation to cell death.
Death receptor activation, ROS, NF-κB and sustained activation of JNK: to die or not to die, that is the question
ROS-dependent sustained activation of JNK: a common step in oxidative stress-dependent cell death
Whatever the mechanism, there is no doubt that ROS-dependent sustained JNK activation can promote cell death, being effective in inducing mitochondrial outer membrane permeabilization; although there is still some controversy on the molecular 'targets' of ROS-activated JNK, a number of hypotheses [187, 194, 199, 209] have been proposed to explain this JNK-mediated event (summarized in Figure 24). The reader should also remember that NF-κB will act to prevent cell death by a number of mechanisms, some of them potentially affecting ROS-mediated sustained JNK activation, such as specifically the reported up-regulation of SOD-2 (that is, the mitochondrial SOD isoform), in TNF-dependent cell death . According to the protective role of NF-κB, it has been shown that NF-κB inhibition can indeed sensitize hepatocytes to TNF-induced apoptosis by means of JNK sustained activation .
Free fatty acids, endoplasmic reticulum stress, oxidative stress and cell death: hepatocyte injury in NAFLD and other CLDs
As elegantly reviewed by Parekh and Anania , liver injury in NAFLD can be considered essentially as the consequence of increased hepatocyte stores of FFAs. Overall, the most relevant mechanisms leading to hepatocyte injury in these metabolically altered conditions involve an excess of FFAs: directly inducing hepatocyte apoptosis and stimulating production of TNF, which is considered in this context as an adipocytokine; increasing Fas ligand binding to Fas (CD-95) receptor in steatotic hepatocytes, leading to apoptosis; leading to impaired mitochondrial or peroxisomal β-oxidation of FFAs accumulating in hepatocytes – as previously described (see the section 'ROS and oxidative stress-related reactive intermediates in NAFLD and NASH: their generation and the role in causing steatosis'), this eventually leads to generation of ROS and lipid peroxidation products, mainly HNE, which in turn may cause cell injury and death; inducing ER stress and the so-called 'unfolded protein response' (UPR), which is potentially able to result in the induction of a form of caspase-dependent cell death involving mitochondria.
ER stress-induced apoptosis has also been implicated in chronic hepatitis C and ALD . With respect to HCV, several studies have shown that HCV-related proteins, including either core proteins as well as E1 and E2 proteins of the envelope, are able to induce overexpression of C/EBP homologous protein (CHOP) via the UPR response, ER depletion of calcium, and apoptosis in liver cells (HCV replicon cells) [215, 216]. Moreover, ER stress and apoptosis were also found in the livers of HCV core transgenic mice . More recently, it has been reported that activation of the Gadd153 gene by HCV in HCV replicon cells is able to sensitizes these cells to oxidant injury  and that both HCV and, interestingly, HBV proteins are able to induce ER stress and to up-regulate protein phosphatase 2A (PP2A) through activation of CREB . In the case of ALD, ER stress involvement has been attributed to hyper-homocysteinemia, since betaine treatment in a mouse model of ALD can promote removal of homocysteine and prevent not only ER stress but also liver steatosis as well as induction of apoptosis. Excellent reviews dedicated to ER stress and HCV- or alcohol-related liver injury published recently by Kaplowitz and coworkers [219–221] also take into consideration the role of ROS.
Ethanol-related redox mechanisms leading to mitochondrial damage and hepatocyte apoptosis
Mitochondria, nitric oxide, RNS and cell death
NO and related RNS are additional key players in the chronic inflammatory settings that characterize chronic wound healing and, more specifically, fibrogenic CLDs. NO and RNS theoretically can promote or prevent apoptotic cell death by interfering with either mitochondria-dependent or mitochondria-independent signalling pathways [235–238]. The most relevant feature is represented by the cellular redox state, with major determinants being the steady state concentration of ROS (mainly O2•-) and the rate between ROS and NO generation; as a rule, NO can act in a preventive way when ROS levels are low and vice versa [235–238].
Cytoprotective action is likely to rely on NO-dependent inhibition of •OH generation in the presence of an iron-catalysed Fenton reaction or on inhibition of propagation of lipid peroxidation (NO being able to react with lipid alkoxyl or lipid hydroperoxyl radicals). In the presence of higher levels of ROS, the right NO/O2•- ratio or the right levels of O2, NO may lead to the generation of highly reactive RNS, such as N2O3 or ONOO-, at levels that are able to induce more aggressive oxidation, nitrosation/S-nitrosation and nitration of different biological macromolecules, eventually leading to either necrotic or apoptotic cell death. Figure 5 summarizes these two alternative scenarios (that is, preventive versus injurious) that can be elicited by NO and RNS, with emphasis on the major molecular mechanisms that may be involved (more details in [235–243]). Here one should just recall that if liver injury is concerned, NO levels (and then those of RNS) are usually increased in CLDs as a consequence of up-regulation of iNOS in hepatocytes, endothelial cells, Kupffer cells and, possibly, HSC/MFs [235–238, 241, 242]. This is likely to be significantly related to levels of TNF in the chronic inflammatory environment as well as to increased translocation of gut-derived endotoxins to the portal circulation, as clearly described in the case of chronic ethanol ingestion and the subsequent interaction of endotoxins with CD14 and TLR-4 in Kupffer cells .
Oxidative stress and induction of cell death in HSC/MFs
In the past decade an emerging issue in hepatology has been that liver fibrosis and even cirrhosis may be potentially reversible. Recovery from either acute or chronic liver injury in animal models is characterized by apoptosis of HSC/MFs, reduction of TIMP (tissue inhibitor of metalloproteinases) levels and progressive degradation of fibrillar fibrotic ECM. In this scenario, the sensitivity of HSCs and HSC/MFs to pro-apoptotic stimuli has been investigated to gain basic knowledge for a putative cell targeted antifibrotic therapy [79–82, 91, 94, 95, 244]. Pertinent to this review, HSC/MFs exposed to oxidative stress can undergo caspase-independent cell death but this usually requires very high concentrations of either H2O2, O2•- or HNE, which are hardly comparable with levels observed in vivo [94, 189, 246]. This has been substantiated mainly for human cells, which, perhaps, may be more resistant than activated rat or murine cells, possibily because human HSC/MFs when activated overexpress Bcl-2 and other survival pathway proteins .
The overall message is that HSC/MFs are likely to survive the conditions of oxidative stress usually operating in CLDs, and rather (see below) are more likely to sustain their pro-inflammatory and pro-fibrogenic responses.
Redox mechanisms and chronic inflammatory response in CLDs
Perpetuation of inflammatory response is a major aetiology-independent driving force for fibrogenic progression in CLDs. In such a chronic scenario, ROS and other reactive intermediates or pro-oxidants (for example, HOCl) released by activated inflammatory cells, either resident (that is, Kupffer cells) or recruited from peripheral blood, may significantly contribute to injury perpetuation. However, they may also (particularly ROS and HNE) act in a paracrine way to affect the response of surrounding cells.
Mediators of oxidative stress, whatever the source (including also ER stress ), the aetiology or metabolic condition can trigger or modulate expression of pro-inflammatory cytokines and chemokines in inflammatory cells and HSC/MFs, mostly through activation of NF-κB [15, 107]. However, oxidative stress mediators also have a significant role in mediating the pro-apoptotic/necrotic effects of certain cytokines, with TNF being possibly the paradigm [107, 186, 187, 248, 249]. This scenario is of particular relevance in some CLDs, such as in human ALD or experimental BDL [243, 250]: both ethanol ingestion or experimental cholestasis can lead to significant translocation of gut derived endotoxins to the portal circulation, where they interact with the surface receptor CD14, resulting in activation of Kupffer cells and increased synthesis of pro-inflammatory cytokines (mainly TNF), eicosanoids, and, once again, ROS and NO. With TNF being an important cause of hepatotoxicity in CLDs, one should recall that hepatocytes are resistant to the pro-apoptotic action of TNF because of the concomitant pro-survival involvement of the NF-κB and PI3K pathway: it is once again the increase in intracellular oxidative stress that can alter the balance, rendering hepatocytes more susceptible to TNF-induced cell death.
Functional responses of inflammatory cells to oxidative stress-related intermediates
Apart from the NF-κB-related increased expression of inflammatory cytokines and chemokines [15, 106, 107], ROS and RNS may act as signalling intermediates by activating tyrosine kinases and inhibiting tyrosine phosphatases, resulting in an enhancement of tyrosine phosphorylation events known to regulate anti-microbial and host defence functions in leukocytes [251–253]. The following concepts should be underlined. First, ROS are likely to be involved in the process of phagocytosis, possibly by leading to amplification of the stimulating signal that follows engagement of Fc receptors on the surface of phagocytic cells, as reported for neutrophils, where ROS seem able to increase either the cross-linking of the FcãRIIIb , as well as by contributing, in neutrophils and macrophages, to amplification of the signal by modulating the activity of the tyrosine kinase Syk, a FcãR downstream signalling element . Second, ROS-mediated inhibitory modulation of the activity of PTPs (for example, CD45, SHP-1, HePTP) has been shown to regulate signalling events involved in the activation of T lymphocytes [256, 257]. In addition, CD45 has long been shown to be relevant for LTB4- and C5a-induced chemotaxis and low affinity FcãR signalling in neutrophils [258, 259]: since ROS have been shown to be potent inhibitors of CD45 , they may interfere with physiological responses to these chemoattractants. Third, ROS may have a role in the apoptosis-related removal of leukocytes during inflammatory responses, as clearly shown for neutrophils and other cells, again by involving tyrosine phosphorylation, CD45 and SHP-1 [261–264], but also through the NOX-dependent, Lyn-mediated activation of the inositol phosphatase SHIP . Similarly, peroxynitrite has also been shown to enhance apoptosis in leukocytes [266, 267].
An additional concept is that intermediates able to cross the leukocyte plasma membrane may affect, in a paracrine way, the behaviour of surrounding cells, as shown originally for endothelial cells [268, 269] and now accepted for many other cells with roles in chronic pro-inflammatory, angiogenic and fibrogenic environments. Accordingly, the lipid soluble aldehyde HNE, at levels compatible with those described in CLDs, up-regulates the expression of the pro-fibrogenic cytokine TGFβ1 in both rat Kupffer cells and human monocyte/macrophage cells . These data may help to explain the scenario observed when using the in vivo experimental CCl4-dependent chronic model: administration of α-tocopherol to rats undergoing this protocol resulted not only in a reduction of oxidative stress, lipid peroxidation and HNE, but also in decreased synthesis of both collagen type I and TGF β1 [271, 272]. Moreover, HNE and other HAKs have been reported to stimulate leukocyte chemotaxis at very low concentrations (0.1 μM; reviewed in [21, 35, 55]), suggesting that α-tocopherol and other chain-breaking antioxidants may prevent experimental liver fibrosis (reviewed in [21, 35, 36, 55]) by either preventing or inhibiting selected phenotypic responses of activated MF-like cells (see the section 'Redox mechanisms in liver fibrogenesis: pro-fibrogenic cells as a functional target' below) or, at least in part, by inhibiting leukocyte recruitment due to HNE or HAKs. Indeed, both ROS and HNE have been shown to up-regulate MCP-1 expression in vivo and in vitro, and then to sustain recruitment/activation of monocytes/macrophages and Kupffer cells as well as to attract HSC/MFs [76, 273, 274].
Pro-inflammatory response of activated HSC/MFs to ROS and HNE: the strange case of MCP-1
A peculiar example of interplay between the generation of reactive intermediates from oxidative stress, inflammatory response and fibrogenesis is represented by the case of MCP-1 (CCL2), which can recruit and activate monocytes and T lymphocytes and plays a major role in the formation and maintenance of the inflammatory infiltrate in different pathological conditions [275–281]. MCP-1, which is overexpressd in human CLDs and experimental models of liver injury [273, 282, 283], can be synthesised by activated macrophages and Kupffer cells as well as by HSC/MFs and biliary epithelial cells [283, 284]. With regard to HSC/MFs, MCP-1 expression is stimulated by pro-inflammatory cytokines, such as IL-1 and TNF [282, 283], thrombin , engagement of integrin receptors  and both ROS and HNE [273, 286]. Indeed, as for TNF or other chemokines such as IL-8 and RANTES, MCP-1 depends on the activation of the redox sensitive transcription factors AP-1 and NF-κB . In human HSC/MFs, ROS can stimulate MCP-1 expression through involvement of NF-κB, whereas HNE does not involve NF-κB and more likely operates through an AP-1-related mechanism , possibly involving activation of PKC , as shown for the PKCβ isoform in monocyte/macrophage cell lines .
Finally, data on human and rat fibrotic livers indicate a direct correlation between oxidative stress, hepatic levels of MCP-1 and the number of monocytes infiltrating the injured liver [273, 284]. Moreover, MCP-1 can significantly stimulate chemotaxis of human HSC/MFs, another putative redox-sensitive pro-fibrogenic feature .
Redox mechanisms in liver fibrogenesis: pro-fibrogenic cells as a functional target
Pro-fibrogenic action of oxidative stress revealed by antifibrotic action of antioxidant molecules
The hypothesis of a causative involvement of oxidative stress in fibrogenesis relies on an impressive number of experimental studies leading to the same final scenario: antioxidant supplementation is able to significantly prevent fibrotic progression in animal models of CLDs by reducing the extent of oxidative stress and/or lipid peroxidation (reviewed in [35, 36], with comments in the section 'Antioxidants as antifibrotic therapeutics for CLDs?' below). The first antioxidants used were silymarin [291, 292], α-tocopherol [271, 272], silybin  and S-adenosylmethionine , and most laboratories were able to describe a temporal sequence of events, suggesting overall that oxidative stress and lipid peroxidation precede or are concomitant with HSC activation and collagen deposition [294–297]. Similarly, experimental studies have also reported that NO was able to prevent both lipid peroxidation and collagen deposition [298, 299].
HNE and ROS can up-regulate pro-collagen type I expression in HSC/MFs: a puzzle that in the end makes sense
ROS and HNE exert a direct pro-fibrogenic action on HSC/MFs: the paracrine effect disclosed
Up-regulation of pro-collagen type I by both ROS and HNE in activated HSC/MFs is a relevant finding that has been confirmed by several different laboratories using either cells of human or rat origin. The first published study in 1993  was on human HSC/MFs exposed to very low levels of HNE (1 μM), resulting in the strongly increased expression of pro-collagen type I, which was prevented by pre-treatment of cells with either vitamin E or the synthetic antioxidant diphenyl-phenylendiamine. After that study, the susceptibility of rat or human HSC/MFs in terms of pro-collagen type I synthesis to oxidative stress mediators was analysed and confirmed using different experimental strategies. The first strategy adopted in the 1990s was to expose HSC/MFs to extracellularly available mediators [189, 301–305], including H2O2, O2•- generated by the xanthine/xanthine-oxidase system, MDA, HAKs of different chain length, and the conditioned medium of normal hepatocytes undergoing oxidative stress [304, 305]. Up-regulation of pro-collagen type I was also obtained later by co-culturing HSC/MFs (which do not express CYP2E1 ) with hepatocytes transfected to overexpress CYP2E1 and then exposed to conditions (for example, ethanol) that result in paracrine exposure of HSC/MFs to CYP2E1-dependent ROS generation [306, 307]. More recently, the connection between oxidative stress, lipid peroxidation and collagen synthesis has once again been confirmed by exposing rat HSC/MFs to F2-isoprostanes . With regard to the pro-fibrogenic mechanism, HNE has been shown in human HSC/MFs to elicit transient activation of JNK isoforms and their nuclear translocation as well as to lead to up-regulation of c-Jun and increased AP-1 binding to DNA ; a very similar JNK/AP-1-dependent pattern, inducing up-regulation of collagen type I, has been shown to operate in rat HSC/MFs exposed to UV irradiation . The overall take-home message from these early studies was clear: ROS, mainly H2O2, HNE and HAKs of different chain length, released in a paracrine way by damaged hepatocytes, endothelial cells or activated inflammatory cells, can easily cross the membrane of HSC/MFs and lead to increased synthesis of pro-collagen type I, a significant component of the fibrillar-like ECM in fibrotic and cirrhotic livers.
ROS generated within HSC/MFs up-regulate collagen type I: the focus is now within the target pro-fibrogenic cell
The next step forward was provided by a series of elegant studies by Nieto and coworkers [306, 310, 311], who adopted the strategy of transfecting rat HSC/MFs to express human CYP2E1: pro-collagen type I transcription and synthesis in transfected cells was proportional to the levels of CYP2E1 and exacerbated by exposure of cells to ethanol or arachidonic acid (that is, conditions leading to CYP2E1-related increased generation of ROS) and prevented by using either antioxidants or specific inhibitors of CYP2E1, such as diallylsulfide. Around the same time, another part of the puzzle was revealed by showing that TGFβ1, the most potent pro-fibrogenic cytokine, was able to up-regulate collagen type I in HSC/MFs by eliciting H2O2-dependent signalling involving the binding of p35 C/EBPβ protein to a specific region of the promoter of the collagen α1(I) gene , an action possibly related to modulation of intracellular levels of GSH  and/or the involvement of p38MAPK . Other signalling pathways and elements have been proposed to mediate ROS-dependent collagen type I expression, including up-regulation of cyclooxygenase 2  or the redox sensitive transcription factor Sp-1 [304, 314], but it should be noted that again the H2O2-dependent involvement of the same C/EBPβ protein was found also to mediate acetaldehyde (ACA)-stimulated up-regulation of collagen type I gene expression . The ACA effect on HSC/MFs was biphasic, with an early phase being mediated by ACA and a late effect due to ACA-induced up-regulation of TGFβ1 expression . The authors suggested in the end that ACA and TGFβ1 were eliciting similar, but not identical, mechanisms to up-regulate collagen type I expression. ACA has also been shown to up-regulate collagen type I expression through activation of JNK, similar to what was also found for HNE  and UV exposure , as finally mediated by the DNA binding protein BTEB . More recently, intracellular generation of H2O2 has been shown to mediate leptin-stimulated enhancement of α 1(I) collagen gene expression in immortalized LX-2 human HSCs : H2O2 was shown to activate Erk1/2 and p38MAPK through active involvement of Janus kinases 1 and 2 (JAK1 and JAK2).
If one considers that extracellular ROS, HNE and F2-isoprostanes are all able to up-regulate TGFβ1 synthesis in either HSC/MFs or mononuclear cells [270, 308, 317], another concept emerges: both the expression and activity of the pro-fibrogenic cytokine TGFβ1 are modulated by ROS or other mediators produced within the target cell, by surrounding cells (in a paracrine manner) or, as suggested for the case of ACA , even in an autocrine manner.
Intracellular generation of ROS can occur in association with cytokine-receptor interaction: NOX isoforms come into the liver fibrogenesis playground
In 2003, Bataller and coworkers  were the first to identify the presence of components of NOX in HSC/MFs, suggesting that the pro-fibrogenic action of Ang II, as already delineated in in vivo and in vitro studies [319, 320], is dependent on the associated activation of NOX and the related ROS-dependent activation of MAPKs, phosphorylation of c-Akt and increased AP-1 DNA binding activity , events blocked by the specific NOX inhibitor DPI (diphenyl-phenyleneiodonium) or the inhibitor of Ang II type 1 receptor (AT1), losartan. More details on the pro-fibrogenic action of Ang II in reference to the related role of NOX can be found in specific reviews [47, 48]. The activation of NOX and intracellular generation of ROS have been involved in the up-regulation of collagen type I expression in HSC/MFs after engulfment by apoptotic bodies from dead hepatocytes , a finding similar to an earlier report showing that macrophage engulfment of apoptotic bodies resulted in increased transcription of TGFβ1 . The initial report by Canbay et al.  was followed by further studies unequivocally showing that apoptotic bodies included in HSC/MFs were signalling through NOX and ROS to up-regulate collagen α 1(I) expression .
ROS and HNE affect other phenotypic responses of HSC/MFs: the specific mediator can make the difference
ROS, but not HNE, mediate proliferation of HSC/MFs
Results obtained with HNE as well as with other HAKs of different chain length substantially differ from those obtained with ROS: HNE and HAKs do not elicit proliferation of human HSC/MFs when employed at pro-fibrogenic doses (1–5 μM) [245, 288, 300, 331] but rather, when used at a pro-fibrogenic dose (1 μM), they induce a block in DNA synthesis by selectively inhibiting PDGF-β receptor intrinsic tyrosine kinase activity and downstream signalling pathways [288, 331]. This peculiar effect of HNE and HAKs is transient, with sensitivity to PDGF-BB being recovered within 48 hours and associated with increased expression of PDGF-β receptor subunits. Interestingly, a similar block in PDGF-dependent signalling and proliferation has been described in human cells when exposed to very high levels of ROS, either H2O2 or superoxide anion [246, 331].
Such a discrepancy between the effects reported for ROS and HNE is likely to depend on the different mechanisms of action: although Uchida and coworkers [23, 332] have proposed that, in some cells, HNE may result in mitochondrial damage and subsequent release of ROS (at high concentrations, however, such as 20 μM or more) or by trapping thiols, HNE is more likely to act as a non-oxidant agent by forming adducts to proteins by means of nucleophilic Michael type reactions [9, 19, 21], as shown in the case of JNK activation . Moreover, HNE does not activate NF-κB [21, 23] in human HSC/MFs  as ROS do, and can even inhibit c-myb , which has been involved in ROS-mediated activation of proliferation . HNE exerts its pro-fibrogenic action only on fully activated human HSC/MFs [21, 189] and, even more relevant, does not apparently act as an activating factor for rat HSCs early in primary culture . This differs from what was suggested for ROS [75, 77, 80, 81] and is likely to occur because quiescent HSCs can remove H2O2 less efficiently than fully activated cells [310, 312], whereas HSC/MFs are more sensitive to HNE because they lack isoforms of GSH-S-transferase and aldehyde dehydrogenase able to remove or inactivate HNE [288, 334]. Finally, HNE seems much more selective in its activity towards HSC/MFs, since it causes the up-regulation of only a limited number of genes, including those encoding collagen type I, TGFβ1, and TIMP-1 [21, 189].
ROS, but not HNE, can significantly affect chemotaxis and ECM remodelling in HSC/MFs: ROS as a signal to migrate
Reports from different laboratories have shown that extracellular generation of O2•- stimulates the migration and even invasiveness (that is, migration in matrigel) of human HSC/MFs [246, 335]. Both laboratories described an O2•--dependent stimulatory effect on the Ras/Erk pathway but opposite results for the activation of PI3K; these effects were prevented by SOD [246, 335] but were not reproduced by exposing cells to H2O2 . Migration, particularly in matrigel, was reported to be also dependent on superoxide-stimulated up-regulation of MMP-2 . The idea that ROS may contribute to HSC/MF migration has been reinforced by studies in which Ang II  and PDGF-BB  stimulated migration in a NOX-dependent way. Recently, a ROS contribution to PDGF-dependent chemotaxis as well as the migratory response to O2•- has been reported to critically involve JNK activation  (E Novo et al., submitted). Once again, HNE behaves in a different way since it affects neither the migration of human HSC/MFs nor the expression of MMPs (MMP-1 and MMP-2) , and, differently from O2•-, which has been reported to up-regulate TIMP-2 , it stimulates only TIMP-1 expression .
A final message from this section
The final response of a pro-fibrogenic target cell to oxidative stress is relatively unpredictable and significantly affected by a number of parameters, including: the steady state concentration of reactive species; the intrinsic state of the target cells (that is, activated versus quiescent); the presence of specific growth factors and cytokines in the microenvironment or of other cellular sources of ROS or HNE; and the concomitant generation of NO in the microenvironment, which may inhibit PDGF-BB-stimulated proliferation through enhanced synthesis of PGE2 and cAMP .
Redox mechanisms in immune reactions associated with CLDs: fuel for chronic inflammation and fibrogenic progression
Several lines of evidence suggest that immune responses may have a significant role in regulating hepatic inflammation in pathological settings of CLDs. As recently reviewed for the case of ALD , oxidative stress can contribute to the progression of CLDs by giving rise to either oxidized or adducted epitopes able to elicit an immune response that, in turn, can contribute to perpetuation of chronic injury and progression of CLDs.
The first studies in this field were performed on ALD patients by showing the existence of circulating antibodies against different epitopes as well as infiltration of both CD4+ and CD8+ T lymphocytes in areas of inflammation and necrosis . The first antibodies characterized in ALD patients were originally those directed against adducts between acetaldehyde and liver proteins . However, recent studies have shown that human ALD patients exhibit significant titres of circulating antibodies directed against a number of epitopes modified by free radicals or oxidative stress reactive intermediates [249, 339]. At present, the best characterized examples of these oxidized or modified epitopes, recognized by circulating antibodies (usually IgG), are: various adducts between liver proteins and hydroxyl-ethyl radicals (HERs), with circulating antibodies recognizing particularly HER-CYP2E1 adducts ; various proteins (mostly not identified) modified by end-products of lipid peroxidation, such as HNE, MDA or lipid hydroperoxides, with titres of related circulating antibodies more prevalent in patients with an advanced stage of ALD ; and lysine residues in proteins modified by the combined reaction of MDA and acetaldehyde, leading to the formation of highly antigenic products that have been defined as malonaldehyde-acetaldehyde adducts [341, 342]. Indeed, as many as 35% of patients with an advanced stage of ALD (but not heavy drinkers with steatosis only) show the presence of a T cell proliferative response against lipid peroxidation protein adducts [340, 343], suggesting that oxidative modifications of epitopes may promote both humoral and cellular immune responses.
Circulating IgG able to recognize epitopes modified by lipid peroxidation-derived reactive molecules has also been detected in patients with NAFLD or affected by chronic hepatitis C [249, 344, 345], indicating that the scenario is of more general value. When NAFLD patients were compared to control subjects, a significantly increased titre of IgG directed against protein adducted with MDA or arachidonic acid hydroperoxide or oxidized cardiolipin was found. The presence of these antibodies in NAFLD patients was independent of age, body mass index, transaminase levels, and the extent of steatosis or the concomitant presence of diabetes. Metabolic changes leading to hepatic steatosis can indeed affect immune functions, possibly by down-regulating the number of liver regulatory T cells, predominantly those with a Th1 cytokine pattern; moreover, adipokines released by adipose tissue have been suggested as additional factors able to affect the regulation of inflammatory and immune response [346, 347].
A very similar scenario (that is, increased titres of IgG against human serum albumin adducted against MDA, HNE, arachidonic acid hydroperoxide and oxidized cardiolipin) has been described in patients affected by chronic hepatitis C. The titres of these antibodies were significantly increased in chronic HCV patients in relation to alcohol intake, but significant increases in these titres was reported even for those patients having only a modest alcohol intake . This study also pointed out that those chronic HCV patients who were also heavy drinkers had statistically significantly more piecemeal necrosis and fibrosis than non-drinkers. Moreover, diffuse piecemeal necrosis was approximately four-fold more frequent in patients who consumed ethanol and had high titres for these antibodies than among patients whose antibody titres were within the control range. Thus, even moderate ethanol consumption can promote oxidative stress in chronic HCV patients, eliciting an immune response that is likely to contribute to the already well known ethanol-dependent worsening of the disease.
With regard to NAFLD patients, the scenario is not completely applicable, with titres of lipid peroxidation-related antibodies apparently unrelated to histological signs of necro-inflammation. However, a carefully performed statistical analysis has revealed that both titres and the frequency of these antibodies were significantly higher in NAFLD patients with bridging fibrosis or cirrhosis compared to patients with no fibrosis or just mild levels of pericellular/perilobular fibrosis . This suggests that the presence of oxidative stress-triggered immune reactions could be an independent predictor of NAFLD progression to an advanced stage of fibrosis and then, likely, as a mechanism potentially contributing to NAFLD progression to NASH.
Oxidative stress-mediated immune responses as fuel for inflammation and fibrogenesis
In CLDs, with ALD patients being a reference for the amount of evidence available, oxidized or modified epitopes may induce humoral as well as cell-mediated immune responses able to significantly contribute to the maintenance of hepatic inflammation in the natural history of ALD. This is crucial in the specific ethanol-related scenario that is often dominated by increased translocation of LPS and endotoxins from the gut to the portal circulation (and the consequent effect on Kupffer cells) and with regard to the fact that ethanol-derived oxidative stress can increase the hepatotoxic action of TNF: indeed, in either chronically ethanol fed rats or alcoholics the presence of high titres of IgG against antigens modified by lipid peroxidation or oxidative stress correlate well with increased TNF production and, quite reasonably, the severity of inflammatory infiltrate .
One can envisage a scenario in which, in the presence of continuous antigen stimulation, cytokines released by lymphocytes can actively sustain Kupffer cell-mediated release of cytokines and chemokines as well as of ROS and NO, which, in turn, may contribute to the perpetuation of oxidative injury, the inflammatory response and fibrogenesis. Interestingly, as many as 60–80% of ALD patients with an advanced stage of the disease have significantly increased levels of anti-phospholipid autoantibodies (aPL-Ab) that recognize oxidized cardiolipin and phosphatidylserine (reviewed in ). aPL-Ab, by recognizing and binding to specifically oxidized epitopes in apoptotic hepatocytes (not in living cells, with phosphatidylserine being oxidized during apoptosis and before exposure on plasma membranes), may affect the ability of Kupffer cells to recognize and phagocytose apoptotic cells. Since phagocytosis of apoptotic cells usually involves increased release of TGFβ1 and IL-10 and down-regulation of TNF and IL-12 production, an impaired disposal of apoptotic hepatocytes by Kupffer cells will negatively affect the anti-inflammatory response of Kupffer cells. Moreover, Kupffer cells as well as other phagocytes may be further activated (pro-inflammatory) by increased recognition of aPL-Ab bound to the surface of apoptotic cells through the IgG Fc receptors. Finally, impaired disposal of apoptotic cells and/or bodies may, at the same time: further increase the inflammatory response because of post-apoptotic cell lysis; maintain conditions that further sustain development of aPL-Ab; and act as a pro-fibrogenic stimulus, as shown by already cited studies in which phagocytosis of apoptotic bodies by HSC/MFs resulted in the NOX- and ROS-dependent increased stimulation of pro-collagen type I synthesis [97, 322].
Antioxidants as antifibrotic therapeutics for CLDs?
This section offers some comments on the potential usefulness of antioxidants as therapeutic agents. Since the literature on this topic is impressive, we offer here just a number of take-home messages (for more detail, see [35, 36, 78, 352–354] and the references therein). The first message is unequivocal: antioxidants significantly prevent experimental liver fibrosis and its progression toward cirrhosis by inhibiting recruitment of inflammatory cells, the number of MFs, and levels of pro-inflammatory and pro-fibrogenic cytokines. This statement applies to different animal models of CLDs and to both naturally occurring and synthetic antioxidants that differ in structure and mechanism of action. The list of effective antioxidant strategies employed in animal models of fibrosis is impressive [35, 36, 77, 80, 352], including treatment with α-tocopherol, carotenoids, the selenium antioxidant ebselen, hydroxyl radical scavengers (such as dimethylsulphoxide of dimethylthiourea), N-acetyl-cysteine, several flavonoids and polyphenols (such as silymarin, quercetin, curcumin, epigallocatechin, and so on), the Japanese herbal medicine sho-saiko-to, the GSH-replenishing compound S-adenosyl methionine, the CYP2E1 inhibitor diallyl sulphide and the supernutrient polyenylphosphatidylcholine.
Unfortunately, results from clinical trials [35, 36, 78, 352–354] are definitively less impressive in terms of changes in laboratory data (some trials report a significant decrease in serum alanine aminotransferase (ALT) levels and few other 'positive' features on selected liver parameters), histological appearance and survival rate. No convincing significant decrease of liver fibrosis has been documented so far, with just the possible exception of some trials with NAFLD/NASH patients treated with vitamin E ([353, 354] and references therein). If one has to outline the possible reasons for such an evident discrepancy between experimental and clinical results, the following may apply. Experimental protocols have usually been designed to make the antioxidant molecule available from the beginning of the protocol, whereas in clinical trials antioxidants have been administered mainly to patients with established cirrhosis or with an advanced stage of CLD; this is relevant if one considers that oxidative stress (as stressed in this review) is likely to represent a constant pro-fibrogenic feature in the natural history of any CLD. Also, in order to match the effective antifibrotic doses employed in experimental studies, human patients should receive very high doses of these compounds, which are either intrinsically difficult to reach or, for some compounds, may raise serious toxicity concerns.
A number of strategies may help to overcome these problems. A first concept is that early diagnosis of the CLD should reasonably allow administration of safe antioxidants as soon as possible during the natural history of the disease to slow down its fibrotic progression. Alternatively, we should use strategies that lead to increased availability of candidate antioxidants with sufficiently rapid rate constants as to be pharmacologically active (that is, even at low doses). Theoretically, at least two different strategies should be tested in properly designed trials: first, the use of more powerful antioxidant molecules, such as flavonoids/polyphenols and/or active principles of herbal compounds, which may also affect fibrotic progression as a consequence of their putative 'signalling' properties able to counteract HSC activation [35, 36, 77, 80, 352, 355]; and second, the use of transfection strategies to deliver antioxidant enzymes such as superoxide dismutase, thioredoxin or heme oxygenase-1 directly to the injured parenchyma or, even more specifically, to HSCs (proof of principle of the efficacy of these strategies has already been reported in experimental models [356–358]).
MP is supported by grants from MUR (Italian Ministry for University and Scientific Research, Rome), from Regione Piemonte (Torino, Italy) and from Fondazione CRT (Torino, Italy).
- Commoner B, Townsend J, Pake GE: Free radicals in biological materials. Nature. 1954, 174: 689-691. 10.1038/174689a0.PubMedView ArticleGoogle Scholar
- Harman D: Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956, 11: 298-300.PubMedView ArticleGoogle Scholar
- Slater TF: Necrogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation. Nature. 1966, 209: 36-40. 10.1038/209036a0.PubMedView ArticleGoogle Scholar
- McCord JM, Fridovich I: Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969, 244: 6049-6055.PubMedGoogle Scholar
- Slater TF: Free Radical Mechanisms in Tissue Injury. 1972, London, UK: Pion LtdGoogle Scholar
- Harman D: The aging process. Proc Natl Acad Sci USA. 1981, 78: 7124-7128. 10.1073/pnas.78.11.7124.PubMed CentralPubMedView ArticleGoogle Scholar
- Cadenas E: Biochemistry of oxygen toxicity. Ann Rev Biochem. 1989, 58: 79-110. 10.1146/annurev.bi.58.070189.000455.PubMedView ArticleGoogle Scholar
- Cadenas E, Davies KJ: Mitochondrial free radical generation, oxidative stress and aging. Free Radic Biol Med. 2000, 29: 222-230. 10.1016/S0891-5849(00)00317-8.PubMedView ArticleGoogle Scholar
- West JD, Marnett LJ: Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol. 2006, 19: 173-194. 10.1021/tx050321u.PubMedView ArticleGoogle Scholar
- White AA, Crawford KM, Patt CS, Lad PJ: Activation of soluble guanylate cyclase from rat lung by incubation or by hydrogen peroxide. J Biol Chem. 1976, 251: 7304-7312.PubMedGoogle Scholar
- Mittal CK, Murad F: Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine 3',5'-monophosphate formation. Proc Natl Acad Sci USA. 1977, 74: 4360-4364. 10.1073/pnas.74.10.4360.PubMed CentralPubMedView ArticleGoogle Scholar
- Ignarro LJ, Kadowitz PJ: The pharmacological and physiological role of cGMP in vascular smooth muscle relaxation. Ann Pharmacol Toxicol. 1985, 25: 171-191. 10.1146/annurev.pa.25.040185.001131.View ArticleGoogle Scholar
- Radomski MW, Palmer RMJ, Moncada S: The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987, 92: 639-646.PubMed CentralPubMedView ArticleGoogle Scholar
- Thannickal VJ, Farnburg BL: Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000, 279: L1005-L1028.PubMedGoogle Scholar
- Dröge W: Free radicals in the physiological control of cell function. Physiol Rev. 2002, 82: 47-95.PubMedView ArticleGoogle Scholar
- Soberman RJ: The expanding network of redox signaling: new observations, complexities, and perspectives. J Clin Invest. 2003, 111: 571-574.PubMed CentralPubMedView ArticleGoogle Scholar
- Chiarugi P, Cirri P: Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci. 2003, 28: 509-514. 10.1016/S0968-0004(03)00174-9.PubMedView ArticleGoogle Scholar
- D'Autrèaux B, Toledano MB: ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007, 8: 813-824. 10.1038/nrm2256.PubMedView ArticleGoogle Scholar
- Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991, 11: 81-128. 10.1016/0891-5849(91)90192-6.PubMedView ArticleGoogle Scholar
- Dianzani MU: 4-Hydroxynonenal and cell signaling. Free Rad Res. 1998, 28: 553-560. 10.3109/10715769809065811.View ArticleGoogle Scholar
- Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU: 4-Hydroxynonenal as a biological signal: molecular bases and pathophysiological implication. Antioxid Redox Signal. 1999, 1: 255-284. 10.1089/ars.1999.1.3-255.PubMedView ArticleGoogle Scholar
- Poli G, Schaur RJ: 4-Hydroxynonenal in the phatomechanisms of oxidative stress. IUBMB Life. 2000, 50: 315-321. 10.1080/15216540051081092.PubMedView ArticleGoogle Scholar
- Uchida K: 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003, 42: 318-343. 10.1016/S0163-7827(03)00014-6.PubMedView ArticleGoogle Scholar
- Witztum JL, Steinberg D: The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med. 2001, 11: 93-102. 10.1016/S1050-1738(01)00111-6.PubMedView ArticleGoogle Scholar
- Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2003, 23: 599-622. 10.1210/er.2001-0039.View ArticleGoogle Scholar
- Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H: Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003, 91: 7A-11A. 10.1016/S0002-9149(02)03144-2.PubMedView ArticleGoogle Scholar
- Pennathur S, Heinecke JW: Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep. 2007, 7: 257-264. 10.1007/s11892-007-0041-3.PubMedView ArticleGoogle Scholar
- Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, Matsuhisa M, Yamasaki Y: Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal. 2007, 9: 355-366. 10.1089/ars.2006.1465.PubMedView ArticleGoogle Scholar
- Papaharalambus CA, Griendling KK: Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. 2007, 17: 48-54. 10.1016/j.tcm.2006.11.005.PubMed CentralPubMedView ArticleGoogle Scholar
- Marnett LJ, Riggins JN, West JD: Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest. 2003, 111: 583-593.PubMed CentralPubMedView ArticleGoogle Scholar
- Wu WS: The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006, 25: 695-705. 10.1007/s10555-006-9037-8.PubMedView ArticleGoogle Scholar
- Klein JA, Ackerman SL: Oxidative stress, cell cycle and neurodegeneration. J Clin Invest. 2003, 111: 785-793.PubMed CentralPubMedView ArticleGoogle Scholar
- Mattson MP: Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006, 8: 1997-2006. 10.1089/ars.2006.8.1997.PubMedView ArticleGoogle Scholar
- Zhu X, Su B, Wang X, Smith MA, Perry G: Causes of oxidative stress in Alzheimer diseases. Cell Mol Life Sci. 2007, 64: 2202-2210. 10.1007/s00018-007-7218-4.PubMedView ArticleGoogle Scholar
- Parola M, Robino G: Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001, 35: 297-306. 10.1016/S0168-8278(01)00142-8.PubMedView ArticleGoogle Scholar
- Zamara E, Novo E, Parola M: Oxidative stress and liver fibrosis: from liver injury to the modulation of cell signaling and response. Liver Diseases: Biochemical Mechanisms and New Therapeutic Insights. Edited by: Ali S, Mann DA, Friedman SL. 2004, Enfield, NH: Science Publishers USA;, 1: 93-114.Google Scholar
- Farrell GC, Larter CZ: Nonalcoholic fatty liver diseases: from steatosis to cirrhosis. Hepatology. 2006, S99-S112. 10.1002/hep.20973. Suppl 1Google Scholar
- Albano E: Alcohol, oxidative stress and free radical damage. Proc Nutr Soc. 2006, 65: 278-280. 10.1079/PNS2006496.PubMedView ArticleGoogle Scholar
- Rahman I, Biswas SK, Kode A: Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol. 2006, 533: 222-239. 10.1016/j.ejphar.2005.12.087.PubMedView ArticleGoogle Scholar
- Rahman I, Yang SR, Biswas SK: Current concepts of redox signaling in the lungs. Antioxid Redox Signal. 2006, 8: 681-689. 10.1089/ars.2006.8.681.PubMedView ArticleGoogle Scholar
- Cho HY, Reddy SP, Kleeberger SR: Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal. 2006, 8: 76-87. 10.1089/ars.2006.8.76.PubMedView ArticleGoogle Scholar
- Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. 1999, Oxford, UK: Oxford University PressGoogle Scholar
- Babior BM: NADPH oxidase: an update. Blood. 1999, 93: 1464-1476.PubMedGoogle Scholar
- Vignais PV: The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci. 2002, 59: 1428-1459. 10.1007/s00018-002-8520-9.PubMedView ArticleGoogle Scholar
- Genestra M: Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal. 2007, 19: 1807-1819. 10.1016/j.cellsig.2007.04.009.PubMedView ArticleGoogle Scholar
- Lambeth JD: Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med. 2007, 43: 332-347. 10.1016/j.freeradbiomed.2007.03.027.PubMed CentralPubMedView ArticleGoogle Scholar
- De Minicis S, Bataller R, Brenner DA: NADPH oxidase in the liver: defensive, offensive, or fibrogenic?. Gastroenterology. 2006, 131: 272-275. 10.1053/j.gastro.2006.05.048.PubMedView ArticleGoogle Scholar
- De Minicis S, Brenner DA: NOX in liver fibrosis. Arch Biochem Biophys. 2007, 462: 266-272. 10.1016/j.abb.2007.04.016.PubMed CentralPubMedView ArticleGoogle Scholar
- Chiarugi P, Fiaschi T: Redox signalling in anchorage-dependent cell growth. Cell Signal. 2007, 19: 672-682. 10.1016/j.cellsig.2006.11.009.PubMedView ArticleGoogle Scholar
- Pritsos CA: Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000, 129: 195-208. 10.1016/S0009-2797(00)00203-9.PubMedView ArticleGoogle Scholar
- Vazquez-Vivar J, Kalyanaramam B: Generation of superoxide from nitric oxide synthase. FEBS. 2000, 481: 304-307. 10.1016/S0014-5793(00)02001-9.View ArticleGoogle Scholar
- Rojkind M, Domininguez-Rosales JA, Nieto N, Greenwel P: Role of hydrogen peroxide and oxidative stress in healing responses. Cell Mol Life Sci. 2002, 59: 1872-1891. 10.1007/PL00012511.PubMedView ArticleGoogle Scholar
- Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ, Burk RF: Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. J Clin Invest. 1992, 92: 2502-2507. 10.1172/JCI116143.View ArticleGoogle Scholar
- Halliwell B, Whiteman M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol. 2004, 142: 231-255. 10.1038/sj.bjp.0705776.PubMed CentralPubMedView ArticleGoogle Scholar
- Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C: Isoprostanes and hepatic fibrosis. Mol Aspects Med. 2008, 29: 43-49. 10.1016/j.mam.2007.09.011.PubMedView ArticleGoogle Scholar
- Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C: F2-isoprostanes are not just markers of oxidative stress. Free Radic Biol Med. 2008, 44: 247-256. 10.1016/j.freeradbiomed.2007.10.004.PubMedView ArticleGoogle Scholar
- Poli G, Parola M: Oxidative damage and fibrogenesis. Free Radic Biol Med. 1997, 22: 287-305. 10.1016/S0891-5849(96)00327-9.PubMedView ArticleGoogle Scholar
- Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007, 87: 315-424. 10.1152/physrev.00029.2006.PubMed CentralPubMedView ArticleGoogle Scholar
- Sase K, Michel T: Expression and regulation of endothelial nitric oxide synthase. Trends Cardiovasc Med. 1997, 7: 28-37. 10.1016/S1050-1738(96)00121-1.PubMedView ArticleGoogle Scholar
- Archer SL, Huang JMC, Hampl V, Nelson DP, Shultz PJ, Weir EK: Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin sensitive K-channel by a cGMP-dependent protein kinase. Proc Natl Acad Sci USA. 1994, 91: 7583-7587. 10.1073/pnas.91.16.7583.PubMed CentralPubMedView ArticleGoogle Scholar
- Beckman JS: Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol. 1996, 9: 836-844. 10.1021/tx9501445.PubMedView ArticleGoogle Scholar
- Beckman JS: The physiological and pathological chemistry of nitric oxide. Nitric Oxide: Principles and Actions. Edited by: Lancaster JR, Orlando FL. 1996, San Diego, CA: Academic Press, 1-82.View ArticleGoogle Scholar
- Butler AR, Megson IL, Wright PG: Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta. 1998, 1425: 168-176.PubMedView ArticleGoogle Scholar
- Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. 1989, Oxford, UK: Oxford University Press, 2Google Scholar
- Young IS, Woodside JV: Antioxidant in health and disease. J Clin Pathol. 2001, 54: 176-186. 10.1136/jcp.54.3.176.PubMed CentralPubMedView ArticleGoogle Scholar
- Berndt C, Lillig CH, Holmgren A: Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2007, 292: 1227-1236. 10.1152/ajpheart.01162.2006.View ArticleGoogle Scholar
- Grune T, Reinheckel T, Davies KJ: Degradation of oxidized proteins in mammalian cells. FASEB J. 1997, 11: 526-534.PubMedGoogle Scholar
- Bader N, Grune T: Protein oxidation and proteolysis. Biol Chem. 2006, 387: 1351-1355. 10.1515/BC.2006.169.PubMedView ArticleGoogle Scholar
- Jung T, Bader N, Grune T: Oxidized proteins: intracellular distribution and recognition by the proteasome. Arc Bioch Bioph. 2007, 462: 231-237. 10.1016/j.abb.2007.01.030.View ArticleGoogle Scholar
- Wu WS, Wu JR, Hu CT: Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev. 2006, 27: 303-314. 10.1007/s10555-008-9112-4.View ArticleGoogle Scholar
- Liu H, Colavitti R, Rovira II, Finkel T: Redox-dependent transcriptional regulation. Circ Res. 2005, 97: 967-974. 10.1161/01.RES.0000188210.72062.10.PubMedView ArticleGoogle Scholar
- Fritz G, Grosch S, Tomicic M, Kaina B: APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology. 2003, 193: 67-78. 10.1016/S0300-483X(03)00290-7.PubMedView ArticleGoogle Scholar
- Tell G, Damante G, Caldwell D, Kelley MR: The intracellular localization of APE/Ref-1: more than a passive phenomenon?. Antioxid Redox Signal. 2005, 7: 367-384. 10.1089/ars.2005.7.367.PubMedView ArticleGoogle Scholar
- Shafritz DA, Oertel M, Menthena A, Nierhoff D, Dabeva MD: Liver stem cells and the prospects for liver reconstitution by transplanted cells. Hepatology. 2006, 43: S89-S98. 10.1002/hep.21047.PubMedView ArticleGoogle Scholar
- Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to issue injury. J Biol Chem. 2000, 275: 2247-2250. 10.1074/jbc.275.4.2247.PubMedView ArticleGoogle Scholar
- Pinzani M, Marra F: Cytokine receptor and signalling in hepatic stellate cells. Semin Liv Dis. 2001, 21: 397-417. 10.1055/s-2001-17554.View ArticleGoogle Scholar
- Friedman SL: Liver fibrosis: from bench to bedside. J Hepatol. 2003, 38: S28-S53. 10.1016/S0168-8278(02)00429-4.View ArticleGoogle Scholar
- Pinzani M, Rombouts K: Liver fibrosis-from the bench to clinical targets. Dig Liver Dis. 2004, 36: 231-242. 10.1016/j.dld.2004.01.003.PubMedView ArticleGoogle Scholar
- Bataller R, Brenner DA: Liver fibrosis. J Clin Invest. 2005, 115: 109-118.Google Scholar
- Friedman SL: Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutics implications. Nat Clin Pract Gastroenterol Hepatol. 2004, 1: 98-105. 10.1038/ncpgasthep0055.PubMedView ArticleGoogle Scholar
- Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008, 88: 125-172. 10.1152/physrev.00013.2007.PubMed CentralPubMedView ArticleGoogle Scholar
- Parola M, Marra F, Pinzani M: Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Asp Med. 2008, 29: 58-66. 10.1016/j.mam.2007.09.002.View ArticleGoogle Scholar
- Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R: Angiogenesis in chronic inflammatory liver disease. Hepatology. 2004, 39: 1185-1195. 10.1002/hep.20193.PubMedView ArticleGoogle Scholar
- Desmet VJ, Roskams T: Cirrhosis reversal: a duel between dogma and myth. J Hepatol. 2004, 40: 860-867. 10.1016/j.jhep.2004.03.007.PubMedView ArticleGoogle Scholar
- Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T: Hepatic stellate cells/myofibroblast subpopulation in fibrotic human and rat livers. J Hepatol. 2002, 36: 200-209. 10.1016/S0168-8278(01)00260-4.PubMedView ArticleGoogle Scholar
- Cassiman D, Roskams T: Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cells research. J Hepatol. 2002, 37: 527-535. 10.1016/S0168-8278(02)00263-5.PubMedView ArticleGoogle Scholar
- Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR: A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 2004, 126: 955-963. 10.1053/j.gastro.2004.02.025.PubMedView ArticleGoogle Scholar
- Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP, Forbes SJ: The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006, 130: 1807-1821. 10.1053/j.gastro.2006.01.036.PubMedView ArticleGoogle Scholar
- Valfrè di Bonzo L, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, Novo E, Sanavio F, Cannito S, Zamara E, Bertero M, Davit A, Francica S, Novelli F, Colombatto S, Fagioli F, Parola M: Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut. 2008, 57: 223-231. 10.1136/gut.2006.111617.PubMedView ArticleGoogle Scholar
- Forbes SJ: Stem cell therapy for chronic liver disease – choosing the right tools for the job. Gut. 2008, 57: 153-155. 10.1136/gut.2007.134247.PubMedView ArticleGoogle Scholar
- Iredale J: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007, 117: 539-548. 10.1172/JCI30542.PubMed CentralPubMedView ArticleGoogle Scholar
- Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzuti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F: Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology. 2005, 42: 1339-1348. 10.1002/hep.20965.PubMedView ArticleGoogle Scholar
- Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M: Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol. 2007, 170: 1942-1953. 10.2353/ajpath.2007.060887.PubMed CentralPubMedView ArticleGoogle Scholar
- Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Monitillo L, Cannito S, Petrai I, Mazzocca A, Bonacchi A, De Franco RS, Colombatto S, Autelli R, Pinzani M, Parola M: Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut. 2006, 55: 1174-1182. 10.1136/gut.2005.082701.PubMed CentralPubMedView ArticleGoogle Scholar
- El-Sharkawy AM, Oakley F, Mann D: The role and regulation of hepatic stellate cells apoptosis in reversal of liver fibrosis. Apoptosis. 2005, 10: 927-939. 10.1007/s10495-005-1055-4.View ArticleGoogle Scholar
- Leist M, Jäättelä M: Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001, 2: 589-598. 10.1038/35085008.PubMedView ArticleGoogle Scholar
- Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ: Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003, 83: 655-663.PubMedView ArticleGoogle Scholar
- Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ: Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 2002, 123: 1323-1330. 10.1053/gast.2002.35953.PubMedView ArticleGoogle Scholar
- Den Hertog J, Groen A, Wijk Van der T: Redox regulation of protein-tyrosine phosphatases. Arch Biochem Biophys. 2005, 434: 11-15. 10.1016/j.abb.2004.05.024.PubMedView ArticleGoogle Scholar
- Tonks KN: Redox redux: revisiting PTPs and the control of cell signaling. Cell. 2005, 121: 667-670. 10.1016/j.cell.2005.05.016.PubMedView ArticleGoogle Scholar
- Tonks NK: Protein tyrosine phosphatases: from genes, to function, to disease. Mol Cell Biol. 2006, 7: 833-845.Google Scholar
- Weiss FU, Daub H, Ullrich A: Novel mechanisms of RTK signal generation. Curr Opin Genet Dev. 1997, 7: 80-86. 10.1016/S0959-437X(97)80113-X.PubMedView ArticleGoogle Scholar
- Gotoh Y, Cooper JA: Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-α signal transduction. J Biol Chem. 1998, 273: 17477-17482. 10.1074/jbc.273.28.17477.PubMedView ArticleGoogle Scholar
- Liu H, Nishitoh H, Ichijo H, Kyriakis JM: Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol. 2000, 20: 2198-2208. 10.1128/MCB.20.6.2198-2208.2000.PubMed CentralPubMedView ArticleGoogle Scholar
- Zingg JM: Modulation of signal transduction by vitamin E. Mol Aspects Med. 2007, 28: 481-506. 10.1016/j.mam.2006.12.009.PubMedView ArticleGoogle Scholar
- Schreck R, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of NFκB transcription factor and HIV-1. Trends Cell Biol. 1991, 1: 39-42. 10.1016/0962-8924(91)90072-H.PubMedView ArticleGoogle Scholar
- Temkin V, Karin M: From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey. Immunol Rev. 2007, 220: 8-21. 10.1111/j.1600-065X.2007.00560.x.PubMedView ArticleGoogle Scholar
- Luo JL, Kamata H, Karin M: IKK/NF-kappaB signaling: balancing life and death – a new approach to cancer therapy. J Clin Invest. 2005, 115: 2625-2632. 10.1172/JCI26322.PubMed CentralPubMedView ArticleGoogle Scholar
- Bonizzi G, Karin M: The two NF-kappaB activation pathways and their role in innate and adaptative immunity. Trends Immunol. 2004, 25: 280-288. 10.1016/j.it.2004.03.008.PubMedView ArticleGoogle Scholar
- Gloire G, Legrand-Poels S, Piette J: NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006, 72: 1493-1505. 10.1016/j.bcp.2006.04.011.PubMedView ArticleGoogle Scholar
- Pietrangelo A: Hereditary hemochromatosis-a new look at an old disease. N Engl J Med. 2004, 350: 2383-2397. 10.1056/NEJMra031573.PubMedView ArticleGoogle Scholar
- Pietrangelo A: Hemochromatosis: an endocrine liver disease. Hepatology. 2007, 46: 1291-1301. 10.1002/hep.21886.PubMedView ArticleGoogle Scholar
- Philippe MA, Ruddell RG, Ramm GA: Role of Iron in hepatic fibrosis: one pieces in the puzzle. World J Gastroenterol. 2007, 13: 4746-4754.PubMedView ArticlePubMed CentralGoogle Scholar
- Pietrangelo A: Hemochromatosis. Gut. 2003, 52: ii23-ii30. 10.1136/gut.52.suppl_2.ii23.PubMed CentralPubMedView ArticleGoogle Scholar
- Pietrangelo A: Hemochromatosis gene modifies corse of hepatitis C viral infection. Gastroenterology. 2003, 124: 1509-1523. 10.1016/S0016-5085(03)00275-0.PubMedView ArticleGoogle Scholar
- Martinelli AL, Ramalho LN, Zucoloto S: Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol. 2004, 19: 91-98. 10.1111/j.1440-1746.2004.03255.x.PubMedView ArticleGoogle Scholar
- Rigamonti C, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G, Boldorini R, Sartori M: Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest. 2002, 32: 28-35. 10.1046/j.1365-2362.2002.0320s1028.x.PubMedView ArticleGoogle Scholar
- Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM: Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res. 2006, 30: 106-112. 10.1111/j.1530-0277.2006.00002.x.PubMedView ArticleGoogle Scholar
- Brittenham GM: Iron chelators and iron toxicity. Alcohol. 2003, 30: 151-158. 10.1016/S0741-8329(03)00101-0.PubMedView ArticleGoogle Scholar
- Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A: Antioxidant activity of sylibin in vivo during chronic iron overload in rats. Gastroenterology. 1995, 109: 1941-1949. 10.1016/0016-5085(95)90762-9.PubMedView ArticleGoogle Scholar
- Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Venturi E: Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest. 1995, 95: 1824-1831. 10.1172/JCI117861.PubMed CentralPubMedView ArticleGoogle Scholar
- Eaton JW, Qian M: Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002, 32: 833-840. 10.1016/S0891-5849(02)00772-4.PubMedView ArticleGoogle Scholar
- Papanikolaou G, Pantopoulos K: Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005, 202: 199-211. 10.1016/j.taap.2004.06.021.PubMedView ArticleGoogle Scholar
- Ramm GA, Ruddell RG: Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis. 2005, 25: 433-449. 10.1055/s-2005-923315.PubMedView ArticleGoogle Scholar
- Cairo G, Recalcati S, Pietrangelo A, Minotti G: The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med. 2002, 32: 1237-1243. 10.1016/S0891-5849(02)00825-0.PubMedView ArticleGoogle Scholar
- Llanos RM, Mercer JF: The molecular basis of copper homeostasis in copper-related disorders. DNA Cell Biol. 2002, 21: 259-270. 10.1089/104454902753759681.PubMedView ArticleGoogle Scholar
- Tao TY, Gitlin JD: Hepatic copper metabolism: insights from genetic disease. Hepatology. 2003, 37: 1241-1247. 10.1053/jhep.2003.50281.PubMedView ArticleGoogle Scholar
- Sokol RJ, Winklhofer-Roob BM, Deveraux MW, McKim JM: Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology. 1995, 109: 1249-1256. 10.1016/0016-5085(95)90585-5.PubMedView ArticleGoogle Scholar
- Novo E, Zamara E, Valfre di Bonzo L, Parola M: Modulation of cell death, signal transduction and cell response by oxidative stress in the progression of chronic liver diseases. Liver Cirrhosis Research. Edited by: Burns JL. Hauppauge, NY: Nova Science Publishers.Google Scholar
- Day CP: Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 2006, 26: 1021-1028. 10.1111/j.1478-3231.2006.01323.x.PubMedView ArticleGoogle Scholar
- Boyer N, Marcellin P: Pathogenesis, diagnosis and management of hepatitis C. J Hepatol. 2000, 32: 98-112. 10.1016/S0168-8278(00)80419-5.PubMedView ArticleGoogle Scholar
- Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchinson J, Albrecht J: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001, 34: 764-767. 10.1016/S0168-8278(01)00055-1.View ArticleGoogle Scholar
- Arteel GE: Oxidant and antioxidant in alcohol-induced liver disease. Gastroenterology. 2003, 124: 778-790. 10.1053/gast.2003.50087.PubMedView ArticleGoogle Scholar
- Nanji AA: Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease. Alcohol. 2004, 34: 21-25. 10.1016/j.alcohol.2004.08.005.PubMedView ArticleGoogle Scholar
- Albano E: Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008, 29: 9-16. 10.1016/j.mam.2007.09.004.PubMedView ArticleGoogle Scholar
- Dey A, Cederbaum AI: Alcohol and oxidative liver injury. Hepatology. 2006, 43: S63-S74. 10.1002/hep.20957.PubMedView ArticleGoogle Scholar
- Parola M, Robino G, Bordone R, Leonarduzzi G, Casini A, Pinzani M, Neve E, Bellomo G, Dianzani MU, Ingelman-Sundberg M, Albano E: Detection of cytochrome P450A (CYP3A) in human hepatic stellate cells. Biochem Biophys Res Commun. 1997, 238: 420-424. 10.1006/bbrc.1997.7307.PubMedView ArticleGoogle Scholar
- Powell EE, Jonsson JR, Clouston AD: Steatosis: co-factor in other liver diseases. Hepatology. 2005, 42: 5-13. 10.1002/hep.20750.PubMedView ArticleGoogle Scholar
- Pessayre D, Fromenty B: NASH: a mithocondrial disease. J Hepatol. 2005, 42: 928-940. 10.1016/j.jhep.2005.03.004.PubMedView ArticleGoogle Scholar
- Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA: Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest. 2004, 113: 1277-1287.PubMed CentralPubMedView ArticleGoogle Scholar
- Bardag-Gorce F, French BA, Nan L, Song H, Nguyen SK, Yong H, Dede J, French SW: CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol. 2006, 81: 191-201. 10.1016/j.yexmp.2006.07.007.PubMedView ArticleGoogle Scholar
- Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346: 1221-1231. 10.1056/NEJMra011775.PubMedView ArticleGoogle Scholar
- Parekh S, Anania FA: Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007, 132: 2191-2207. 10.1053/j.gastro.2007.03.055.PubMedView ArticleGoogle Scholar
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic sindrome. Hepatology. 2003, 38: 536.View ArticleGoogle Scholar
- Tilg H, Hotamisligil GS: Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006, 131: 934-945. 10.1053/j.gastro.2006.05.054.PubMedView ArticleGoogle Scholar
- Day CP, James OF: Steatohepatitis: a tale of two 'hits'?. Gastroenterology. 1998, 114: 842-845. 10.1016/S0016-5085(98)70599-2.PubMedView ArticleGoogle Scholar
- Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005, 48: 634-642. 10.1007/s00125-005-1682-x.PubMedView ArticleGoogle Scholar
- Reid AE: Nonalcoholic steatohepatitis. Gastroenterology. 2001, 121: 710-723. 10.1053/gast.2001.27126.PubMedView ArticleGoogle Scholar
- Robertson G, Leclercq I, Farrell GC: Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001, 281: G1135-1139.PubMedGoogle Scholar
- Mehta K, Van Thiel DH, Shah N, Mobarhan S: Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002, 60: 289-293. 10.1301/002966402320387224.PubMedView ArticleGoogle Scholar
- Day CP: Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. Gut. 2002, 50: 585-588. 10.1136/gut.50.5.585.PubMed CentralPubMedView ArticleGoogle Scholar
- Leclerq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non alcoholic steatohepatitis. J Clin Invest. 2000, 105: 1067-1075. 10.1172/JCI8814.View ArticleGoogle Scholar
- Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C: Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998, 27: 128-133. 10.1002/hep.510270121.PubMedView ArticleGoogle Scholar
- Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004, 114: 147-152.PubMed CentralPubMedView ArticleGoogle Scholar
- Serviddio G, Sastre J, Bellanti F, Vina J, Vendemmiale G, Altomare E: Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Asp Med. 2008, 29: 22-35. 10.1016/j.mam.2007.09.014.View ArticleGoogle Scholar
- Crabb DW, Liangpunsakul S: Alcohol and lipid metabolism. J Gastroenterol Hepatol. 2006, 21: S56-S60. 10.1111/j.1440-1746.2006.04582.x.PubMedView ArticleGoogle Scholar
- Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a casual role in multiple forms of insulin resistance. Nature. 2006, 440: 944-948. 10.1038/nature04634.PubMedView ArticleGoogle Scholar
- Bloch-Damti A, Basham N: Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal. 2005, 7: 1553-1567. 10.1089/ars.2005.7.1553.PubMedView ArticleGoogle Scholar
- Shattemberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ: Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signalling. J Biol Chem. 2005, 280: 9887-9894. 10.1074/jbc.M410310200.View ArticleGoogle Scholar
- Xu Z, Chen L, Leung L, Yen TSB, Lee C, Chan JY: Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA. 2005, 102: 4120-4125. 10.1073/pnas.0500660102.PubMed CentralPubMedView ArticleGoogle Scholar
- Parola M, Novo E: Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. J Hepatol. 2005, 43: 1096-1097. 10.1016/j.jhep.2005.09.008.View ArticleGoogle Scholar
- Loguercio C, Federico A: Oxidative stress in viral and alcoholis hepatitis. Free Radic Biol Med. 2003, 34: 1-10. 10.1016/S0891-5849(02)01167-X.PubMedView ArticleGoogle Scholar
- Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyosh H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001, 61: 4365-4370.PubMedGoogle Scholar
- Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002, 122: 366-375. 10.1053/gast.2002.30983.PubMedView ArticleGoogle Scholar
- Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM: Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology. 2002, 122: 352-365. 10.1053/gast.2002.31001.PubMedView ArticleGoogle Scholar
- Gong G, Waris G, Tanveer R, Siddiqui A: Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA. 2001, 98: 9599-604. 10.1073/pnas.171311298.PubMed CentralPubMedView ArticleGoogle Scholar
- Qadri I, Iwahashi M, Capasso JM, Hopkin MW, Flores S, Schaack J, Simon FR: Induced oxidative stress and activated expression of manganese superoxide dismutase (MnSOD) during hepatitis C virus replication: Role of JNK, p38MAPK AP-1. Biochem J. 2004, 378: 919-928. 10.1042/BJ20031587.PubMed CentralPubMedView ArticleGoogle Scholar
- Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A: Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkBα and its degradation by calpain protease. J Biol Chem. 2003, 278: 40778-40787. 10.1074/jbc.M303248200.PubMedView ArticleGoogle Scholar
- Seronello S, Sheikh MY, Choi J: Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Rad Biol Med. 2007, 43: 869-882. 10.1016/j.freeradbiomed.2007.05.036.PubMedView ArticleGoogle Scholar
- Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I: Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008, 134: 226-238. 10.1053/j.gastro.2007.10.011.PubMedView ArticleGoogle Scholar
- Alpini G, McGill JM, La Russo NF: The pathobiology of biliary epithelia. Hepatology. 2002, 35: 1256-1268. 10.1053/jhep.2002.33541.PubMedView ArticleGoogle Scholar
- Xia X, Demorrow S, Francis H, Glaser S, Alpini G, Marzioni M, Fava G, Lesage G: Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis. 2007, 27: 401-12. 10.1055/s-2007-991516.PubMedView ArticleGoogle Scholar
- Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, Marra F, Herbst H, Alpini G, Milani S: Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol. 1999, 31: 100-109. 10.1016/S0168-8278(99)80169-X.PubMedView ArticleGoogle Scholar
- Parola M, Leonarduzzi G, Robino G, Albano E, Poli G, Dianzani MU: On the role of lipid peroxidation in the pathogenesis of liver damage induced by long-standing cholestasis. Free Radic Biol Med. 1996, 20: 351-359. 10.1016/0891-5849(96)02055-2.PubMedView ArticleGoogle Scholar
- Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K: In situ detection of oxidative DNA damage, 8-hydroxy-deoxyguanosine, in chronic human liver disease. J Hepatol. 2001, 35: 613-618. 10.1016/S0168-8278(01)00171-4.PubMedView ArticleGoogle Scholar
- Tsuneyama K, Harada K, Kono N, Sasaki M, Saito T, Gershwin ME, Ikemoto M, Aria H, Nakanuma Y: Damaged interlobular bile ducts in primary biliary cirrhosis show reduced expression of glutathione-S-transferase-pi and aberrant expression of 4-hydroxynonenal. J Hepatol. 2002, 37: 176-183. 10.1016/S0168-8278(02)00105-8.PubMedView ArticleGoogle Scholar
- Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW: Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta. 2003, 1637: 142-150.PubMedView ArticleGoogle Scholar
- Salunga TL, Cui ZG, Shimoda S, Zheng HC, Nomato K, Kondo T, Takano Y, Selmi C, Alpini G, Gershwin ME, Tsuneyama K: Oxidative-stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J Autoimmun. 2007, 29: 78-86. 10.1016/j.jaut.2007.04.002.PubMedView ArticleGoogle Scholar
- Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ: Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology. 2001, 33: 616-626. 10.1053/jhep.2001.22702.PubMedView ArticleGoogle Scholar
- Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ: Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998, 4: 165-178. 10.1007/s0089480040165.PubMed CentralPubMedView ArticleGoogle Scholar
- Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ: A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998, 101: 2790-2799. 10.1172/JCI1325.PubMed CentralPubMedView ArticleGoogle Scholar
- Gumpricht E, Dahl R, Yerushalmi B, Devereaux MW, Sokol RJ: Nitric oxide ameliorates hydrophobic bile acid-induced apoptosis in isolated rat hepatocytes by non-mitochondrial pathways. J Biol Chem. 2002, 277: 25823-25830. 10.1074/jbc.M112305200.PubMedView ArticleGoogle Scholar
- Bataller R, North KE, Brenner DA: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003, 37: 493-503. 10.1053/jhep.2003.50127.PubMedView ArticleGoogle Scholar
- Kaplowitz N: Mechanisms of liver cell injury. J Hepatol. 2000, 32: 39-47. 10.1016/S0168-8278(00)80414-6.PubMedView ArticleGoogle Scholar
- Jaeschke H, Gore GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ: Mechanisms of hepatotoxicity. Toxicol Sci. 2002, 65: 166-176. 10.1093/toxsci/65.2.166.PubMedView ArticleGoogle Scholar
- Mahli H, Gores GJ, Lemasters JJ: Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology. 2006, 43: S31-44. 10.1002/hep.21062.View ArticleGoogle Scholar
- Kaplowitz N: Liver biology and pathobiology. Hepatology. 2006, 44: 282-10.1002/hep.21255.View ArticleGoogle Scholar
- Arnaiz SL, Llesuy S, Cutrin JC, Boveris A: Oxidative stress by acute acetominophen administration in mouse liver. Free Radic Biol Med. 1995, 19: 303-310. 10.1016/0891-5849(95)00023-Q.View ArticleGoogle Scholar
- Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, Parola M: 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol. 2004, 40: 60-68. 10.1016/S0168-8278(03)00480-X.PubMedView ArticleGoogle Scholar
- Patel T, Bronk SF, Gores GJ: Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest. 1994, 94: 2183-2192. 10.1172/JCI117579.PubMed CentralPubMedView ArticleGoogle Scholar
- Parola M, Robino G, Dianzani MU: 4-Hydroxy-2,3-alkenals as molecular mediators of oxidative stress in the pathogenesis of liver fibrosis. Int J Mol Med. 1999, 4: 425-432.PubMedGoogle Scholar
- Guicciardi ME, Gores GJ: Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005, 54: 1024-1033. 10.1136/gut.2004.053850.PubMed CentralPubMedView ArticleGoogle Scholar
- Festjens N, Vanden Berghe T, Vandenabeele P: Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006, 1757: 1371-1387. 10.1016/j.bbabio.2006.06.014.PubMedView ArticleGoogle Scholar
- Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P: RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Diff. 2007, 14: 400-410. 10.1038/sj.cdd.4402085.View ArticleGoogle Scholar
- Vanden Berghe T, Declercq W, Vandenabeele P: NADPH oxidases: new players in TNF-induced necrotic cell death. Mol Cell. 2007, 26: 769-771. 10.1016/j.molcel.2007.06.002.PubMedView ArticleGoogle Scholar
- Green DR, Kroemer G: The pathophysiology of mitochondrial cell death. Science. 2004, 305: 626-629. 10.1126/science.1099320.PubMedView ArticleGoogle Scholar
- Micheau O, Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003, 114: 181-190. 10.1016/S0092-8674(03)00521-X.PubMedView ArticleGoogle Scholar
- Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000.PubMedView ArticleGoogle Scholar
- Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M: The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006, 124: 601-613. 10.1016/j.cell.2006.01.021.PubMedView ArticleGoogle Scholar
- Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997, 386: 517-521. 10.1038/386517a0.PubMedView ArticleGoogle Scholar
- Ding WX, Ni HM, DiFrancesca D, Stolz DB, Yin XM: Bid-dependent generation of oxigen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology. 2004, 40: 403-413. 10.1002/hep.20310.PubMedView ArticleGoogle Scholar
- Kim YS, Morgan MJ, Choksi S, Liu ZG: TNF-Induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell. 2007, 26: 675-687. 10.1016/j.molcel.2007.04.021.PubMedView ArticleGoogle Scholar
- Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M: Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005, 120: 649-661. 10.1016/j.cell.2004.12.041.PubMedView ArticleGoogle Scholar
- Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G: Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 2004, 119: 529-542. 10.1016/j.cell.2004.10.017.PubMedView ArticleGoogle Scholar
- Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2: 222-228. 10.1093/embo-reports/kve046.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu Y, Min W: Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res. 2002, 90: 1259-1266. 10.1161/01.RES.0000022160.64355.62.PubMedView ArticleGoogle Scholar
- Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G, Susin SA: NADPH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem. 2001, 276: 16391-16398. 10.1074/jbc.M010498200.PubMedView ArticleGoogle Scholar
- Zangar RC, Davydov DR, Verma S: Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. 2004, 36: 1303-1316.Google Scholar
- Deng Y, Ren X, Yang L, Lin Y, Wu X: A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell. 2003, 115: 61-70. 10.1016/S0092-8674(03)00757-8.PubMedView ArticleGoogle Scholar
- Jones PL, Ping D, Boss JM: Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EPB-beta and NF-kappaB. Mol Cell Biol. 1997, 17: 6970-6981.PubMed CentralPubMedView ArticleGoogle Scholar
- Lin H, Chan R, Lo M, Czaja MJ: NF-κB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology. 2002, 35: 772-778. 10.1053/jhep.2002.32534.View ArticleGoogle Scholar
- Malhotra JD, Kaufman RJ: The endoplasmic reticulum and the unfolded protein response. Sem Cell Dev Biol. 2007, 18: 716-731. 10.1016/j.semcdb.2007.09.003.View ArticleGoogle Scholar
- Marciniak SJ, Ron D: Endoplasmic reticulum stress signaling in disease. Physiol Rev. 2006, 86: 1133-1149. 10.1152/physrev.00015.2006.PubMedView ArticleGoogle Scholar
- Wei Y, Wang D, Topczewski F, Pagliassotti MJ: Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006, 291: E275-E281. 10.1152/ajpendo.00644.2005.PubMedView ArticleGoogle Scholar
- Benali-Furet N, Chami M, Ludivine H, DeGiorgi F, Vernejoul F, Lagorce D, Buscail L, Bartenschlager R, Ichas F, Rizzuto R, Paterlini-Brechot P: Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and calcium depletion. Oncogene. 2005, 24: 4921-4933. 10.1038/sj.onc.1208673.PubMedView ArticleGoogle Scholar
- Chan SW, Egan PA: Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. FASEB J. 2005, 19: 1510-1512.PubMedGoogle Scholar
- Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Venditelli F, Costantino A, Geraci A, Rapicetta M: Activation of the ER stress gene GADD153 by hepatitis C virus sensitized cells to oxidant injury. Virus Res. 2007, 126: 128-138. 10.1016/j.virusres.2007.02.006.PubMedView ArticleGoogle Scholar
- Christen V, Treves S, Duong FH, Heim MH: Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatases 2A. Hepatology. 2007, 46: 558-565. 10.1002/hep.21611.PubMedView ArticleGoogle Scholar
- Kaplowitz N, Ji C: Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. J Gastroenterol Hepatol. 2006, 21: S7-9. 10.1111/j.1440-1746.2006.04581.x.PubMedView ArticleGoogle Scholar
- Ji C, Kaplowitz N: ER stress: can the liver cope?. J Hepatol. 2006, 45: 321-333. 10.1016/j.jhep.2006.06.004.PubMedView ArticleGoogle Scholar
- Kaplowitz N, Than TA, Shinohara M, Ji C: Endoplasmic reticulum stress and liver injury. Sem Liv Dis. 2007, 27: 367-377. 10.1055/s-2007-991513.View ArticleGoogle Scholar
- Yip WW, Burt AD: Alcoholic liver disease. Semin Diagn Pathol. 2006, 23: 149-160. 10.1053/j.semdp.2006.11.002.PubMedView ArticleGoogle Scholar
- Bailey SM, Cunningham CC: Contribution of mitochondria to oxidative stress associated with alcohol liver disease. Free Rad Biol Med. 2002, 32: 11-16. 10.1016/S0891-5849(01)00769-9.PubMedView ArticleGoogle Scholar
- Fernandez-Checa JC, Kaplowitz N: Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol. 2005, 204: 263-273. 10.1016/j.taap.2004.10.001.PubMedView ArticleGoogle Scholar
- Hoek JB, Cahill A, Pastorino JG: Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology. 2002, 122: 2049-2063. 10.1053/gast.2002.33613.PubMed CentralPubMedView ArticleGoogle Scholar
- Mansouri A, Fromenty B, Berson A, Robin MA, Grimbert S, Beaugrand M, Erlinger S, Pessayre D: Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholics. J Hepatol. 1997, 27: 96-102. 10.1016/S0168-8278(97)80286-3.PubMedView ArticleGoogle Scholar
- Adachi M, Higuchi H, Miura S, Azuma T, Inokuchi S, Saito H, Kato S, Ishii H: Bax interacts with voltage-dependent anion channel and mediates ethanol-induced apoptosis in rat hepatocytes. Am J Physiol. 2004, 287: G695-G705.Google Scholar
- Adachi M, Ishii H: Role of mitochondria in alcoholic liver injury. Free Rad Biol Med. 2002, 32: 487-491. 10.1016/S0891-5849(02)00740-2.PubMedView ArticleGoogle Scholar
- Caro AA, Cederbaum AI: Oxidative stress, toxicology and pharmacology of CYP2E1. Ann Rev Pharmacol Toxicol. 2004, 44: 27-42. 10.1146/annurev.pharmtox.44.101802.121704.View ArticleGoogle Scholar
- Fromenty B, Pessayre D: Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol. 1997, 26 (Suppl 2): 43-53. 10.1016/S0168-8278(97)80496-5.PubMedView ArticleGoogle Scholar
- Hines IN, Wheeler MD: Recent advances in alcoholic liver disease. III. Role of the innate immune response in alcoholic hepatitis. Am J Physiol. 2004, 287: G310-G314. 10.1152/ajpcell.00534.2003.View ArticleGoogle Scholar
- Hoek JB, Pastorino JG: Alcohol and mitochondria: a dysfunctional relationship. Semin Liver Dis. 2004, 24: 257-272. 10.1055/s-2004-832939.PubMedView ArticleGoogle Scholar
- Shulga N, Hoek JB, Pastorino JG: Elevated PTEN levels account for the increased sensitivity of ethanol-exposed cells to tumor necrosis factor cytotoxicity. J Biol Chem. 2005, 280: 9416-9424. 10.1074/jbc.M409505200.PubMedView ArticleGoogle Scholar
- Sampey BP, Stewart BJ, Petersen DR: Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase 1/2 activity via 4-hydroxynonenal. J Biol Chem. 2007, 282: 1925-1937. 10.1074/jbc.M610602200.PubMed CentralPubMedView ArticleGoogle Scholar
- Li J, Billiar TR: Nitric oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am J Physiol. 1998, 276: G1069-G1073.Google Scholar
- Clemens MG: Nitric oxide in liver injury. Hepatology. 1999, 30: 1-5. 10.1002/hep.510300148.PubMedView ArticleGoogle Scholar
- Boyd CS, Cadenas E: Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem. 2002, 383: 411-423. 10.1515/BC.2002.045.PubMedView ArticleGoogle Scholar
- Kim PKM, Zuckerbraun BS, Otterbein LE, Vodovotz Y, Billiar TR: Till cell death do us part: nitric oxide and mechanisms of hepatotoxicity. Biol Chem. 2004, 385: 11-15. 10.1515/BC.2004.002.PubMedGoogle Scholar
- Vodovotz Y, Kim PKM, Bagci EZ, Ermentrout GB, Chow CC, Bahar I, Billiar TR: Inflammatory modulation of hepatocytes apoptosis by nitric oxide: in vivo, in vitro, and in silico studies. Curr Mol Med. 2004, 4: 753-762. 10.2174/1566524043359944.PubMedView ArticleGoogle Scholar
- Grisham MB, Jourd'Heuil D, Wink DA: Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implication in inflammation. Am J Physiol. 1998, 278: G315-G321.Google Scholar
- Shash V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC: Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest. 1997, 100: 2923-2930. 10.1172/JCI119842.View ArticleGoogle Scholar
- Rockey DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Semis Liver Dis. 2001, 21: 337-349. 10.1055/s-2001-17551.View ArticleGoogle Scholar
- Rao RK, Seth A, Sheth P: Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol. 2004, 286: G881-G884.Google Scholar
- Iredale JP: Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis. 2001, 21: 427-436. 10.1055/s-2001-17557.PubMedView ArticleGoogle Scholar
- Robino G, Parola M, Marra F, Caligiuri A, De Franco RM, Zamara E, Bellomo G, Gentilini P, Pinzani M, Dianzani MU: Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem. 2000, 275: 40561-40567. 10.1074/jbc.M007694200.PubMedView ArticleGoogle Scholar
- Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cannito S, Antonaci C, Colombatto S, Pinzani M, Parola M: Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut. 2006, 55: 90-97. 10.1136/gut.2005.069633.PubMed CentralPubMedView ArticleGoogle Scholar
- Malhotra JD, Kaufman RJ: Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?. Antioxid Redox Signal. 2007, 9: 2277-2293. 10.1089/ars.2007.1782.PubMedView ArticleGoogle Scholar
- Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. J Mol Med. 2007, 14: 72-81.Google Scholar
- Vidali M, Stewart FS, Albano E: Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med. 2008, 14: 63-71. 10.1016/j.molmed.2007.12.005.PubMedView ArticleGoogle Scholar
- Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, McKim SE, Parsons C, Rippe RA, Wheeler MD: LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol. 2006, 290: G1318-G1328.Google Scholar
- Fialkow L, Wang Y, Downey GP: Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Rad Biol Med. 2007, 42: 153-164. 10.1016/j.freeradbiomed.2006.09.030.PubMedView ArticleGoogle Scholar
- Forman HJ, Torres M: Redox signaling in macrophages. Mol Asp Med. 2001, 22: 89-216. 10.1016/S0098-2997(01)00011-5.View ArticleGoogle Scholar
- Thakur V, McMullen MR, Pritchard MT, Nagy LE: Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol. 2007, 22: S53-S56. 10.1111/j.1440-1746.2006.04650.x.PubMedView ArticleGoogle Scholar
- Salmon J, Millard SS, Brogle NL, Kimberly RP: Fc gamma receptor IIIb enhances Fc gamma receptor Ila function in an oxidant-dependent and allele-sensitive manner. J Clin Invest. 1995, 95: 2877-2885. 10.1172/JCI117994.PubMed CentralPubMedView ArticleGoogle Scholar
- Greenberg S, Chang P, Silverstein SC: Tyrosine phosphorylation of the gamma subunit of Fc gamma receptors, p72syk, and paxillin during Fc receptor-mediated phagocytosis in macrophages. J Biol Chem. 1994, 269: 3897-3902.PubMedGoogle Scholar
- Holmes N: CD45: all is not yet crystal clear. Immunology. 2006, 117: 145-155. 10.1111/j.1365-2567.2005.02265.x.PubMed CentralPubMedView ArticleGoogle Scholar
- Lee K, Esselman WJ: Inhibition of PTPs by H2O2 regulates the activation of distinct MAPK pathways. Free Radic Biol Med. 2002, 33: 1121-1132. 10.1016/S0891-5849(02)01000-6.PubMedView ArticleGoogle Scholar
- Harvath L, Balke JA, Christiansen NP, Russell AA, Skubitz KM: Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. J Immunol. 1991, 146: 949-957.PubMedGoogle Scholar
- Hoffmeyer F, Witte K, Gebhardt U, Schmidt RE: The low affinity Fc gamma RIIa and Fc gamma RIIIb on polymorphonuclear neutrophil are differentially regulated by CD45 phosphatase. J Immunol. 1995, 155: 4016-4023.PubMedGoogle Scholar
- Fialkow L, Chan CK, Downey GP: Inhibition of CD45 during neutrophil activation. J Immunol. 1997, 158: 5409-5417.PubMedGoogle Scholar
- Yasui K, Kobayashi N, Yamazaki T, Agematsu K, Matsuzaki S, Ito S, Nakata S, Baba A, Koike K: Superoxide dismutase (SOD) as a potential inhibitory mediator of inflammation via neutrophil apoptosis. Free Radic Res. 2005, 39: 755-762. 10.1080/10715760500104066.PubMedView ArticleGoogle Scholar
- Melley DD, Evans TW, Quinlan GJ: Redox regulation of neutrophil apoptosis and the systemic inflammatory response syndrome. Clin Sci (London). 2005, 108: 413-424.View ArticleGoogle Scholar
- Zhang B, Hirahashi J, Cullere X, Mayadas TN: Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis: cross-talk between caspase 8, reactive oxygen species, and MAPK/ERK activation. J Biol Chem. 2003, 278: 28443-28454. 10.1074/jbc.M210727200.PubMedView ArticleGoogle Scholar
- Fortin M, Steff AM, Felberg J, Ding I, Schraven B, Johnson P, Hugo P: Apoptosis mediated trough CD45 is independent of its phosphatase activity and association with leukocyte phosphatase-associated phosphoprotein. J Immunol. 2002, 168: 6084-6609.PubMedView ArticleGoogle Scholar
- Gardai S, Whitlock BB, Helgason C, Ambruso D, Fadok V, Bratton D, Henson PM: Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002, 277: 5236-5246. 10.1074/jbc.M110005200.PubMedView ArticleGoogle Scholar
- Blaylock MG, Cuthbertson BH, Galley HF, Ferguson NR, Webster NR: The effect of nitric oxide and peroxynitrite on apoptosis in human polynorphonuclear leukocytes. Free Radic Biol Med. 1998, 25: 748-752. 10.1016/S0891-5849(98)00108-7.PubMedView ArticleGoogle Scholar
- Ward C, Wong TH, Murray J, Rahman I, Haslett C, Chilvers ER, Rossi AG: Induction of human neutrophil apoptosis by nitric oxide donors: evidence for caspase-dependent, cyclic-GMP-independent, mechanism. Biochem Pharmacol. 2000, 59: 305-314. 10.1016/S0006-2952(99)00329-9.PubMedView ArticleGoogle Scholar
- Natarajan V, Taher MM, Roehm B, Parinandi NL, Schmid HH, Kiss Z, Garcia JG: Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty liver hydroperoxide. J Biol Chem. 1993, 268: 930-937.PubMedGoogle Scholar
- Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM: Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol. 1991, 112: 749-759. 10.1083/jcb.112.4.749.PubMedView ArticleGoogle Scholar
- Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G: The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates trasforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J. 1997, 11: 851-857.PubMedGoogle Scholar
- Parola M, Leonarduzzi G, Biasi F, Albano E, Biocca ME, Poli G, Dianzani MU: Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and chirrosis. Hepatology. 1992, 16: 1014-1021. 10.1002/hep.1840160426.PubMedView ArticleGoogle Scholar
- Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G: Vitamin E dietary supplementation inhibits trasforming growth factor β1 gene expression in the rat liver. FEBS Lett. 1992, 308: 266-270. 10.1016/0014-5793(92)81290-3.View ArticleGoogle Scholar
- Marra F, DeFranco R, Grappone C, Parola M, Milani S, Leonarduzzi G, Pastacaldi S, Wenzel UO, Pinzani M, Dianzani MU, Laffi G, Gentilini P: Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med. 1999, 47: 66-75.PubMedGoogle Scholar
- Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, Mastrocola R, Novo E, Bertolani C, Milani S, Vizzutti F, Vercelli A, Pinzani M, Laffi G, LaVilla G, Parola M, Marra F: Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol. 2007, 46: 230-238. 10.1016/j.jhep.2006.09.007.PubMedView ArticleGoogle Scholar
- Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ: Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry. 1988, 27: 4162-4168. 10.1021/bi00411a039.PubMedView ArticleGoogle Scholar
- Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B: Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J. 1994, 8: 1055-1060.PubMedGoogle Scholar
- Rollins BJ: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today. 1996, 2: 198-204. 10.1016/1357-4310(96)88772-7.PubMedView ArticleGoogle Scholar
- Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Glaude R, Rollins B: In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol. 1997, 62: 577-580.PubMedGoogle Scholar
- Shin WS, Szuba A, Rockson SG: The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002, 160: 91-102. 10.1016/S0021-9150(01)00571-8.PubMedView ArticleGoogle Scholar
- Daly C, Rollins BJ: Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptative immunity: therapeutic opportunities and controversies. Microcirculation. 2003, 10: 247-257.PubMedView ArticleGoogle Scholar
- Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res. 2004, 95: 858-866. 10.1161/01.RES.0000146672.10582.17.PubMedView ArticleGoogle Scholar
- Marra F, Valente AJ, Pinzani M, Abboud HE: Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest. 1993, 92: 1674-1680. 10.1172/JCI116753.PubMed CentralPubMedView ArticleGoogle Scholar
- Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y: Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leukocyte Biol. 1994, 55: 120-126.PubMedGoogle Scholar
- Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P: Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998, 152: 423-430.PubMed CentralPubMedGoogle Scholar
- Marra F, Valente AJ, Grandaliano G, Abboud HE: Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1. Hepatology. 1995, 22: 780-787.PubMedGoogle Scholar
- Xu Y, Rojkind M, Czaja MJ: Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. Gastroenterology. 1996, 110: 1870-1877. 10.1053/gast.1996.v110.pm8964413.PubMedView ArticleGoogle Scholar
- Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL: Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J Leukoc Biol. 1999, 65: 291-298.PubMedGoogle Scholar
- Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, Chiarugi P, Camandola S, Poli G, Waeg G, Gentilini P, Dianzani MU: HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest. 1998, 102: 1942-1950. 10.1172/JCI1413.PubMed CentralPubMedView ArticleGoogle Scholar
- Marinari UM, Nitti M, Pronzato MA, Domenicotti C: Role of PKC-dependent pathways in HNE-induced cell protein transport and secretion. Mol Asp Med. 2003, 24: 205-211. 10.1016/S0098-2997(03)00015-3.View ArticleGoogle Scholar
- Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, Gentilini P: Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology. 1999, 29: 140-148. 10.1002/hep.510290107.PubMedView ArticleGoogle Scholar
- Mourelle M, Muriel P, Favari L, Franco T: Prevention of CCl4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol. 1989, 3: 183-191.PubMedView ArticleGoogle Scholar
- Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D: Silymarin retard collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997, 26: 643-649. 10.1002/hep.510260316.PubMedView ArticleGoogle Scholar
- Gasso M, Rubio M, Varala G, Cabre M, Cavalleria J, Alonso E, Deulofem R, Camps , Gimenez A, Pajares M, Pares A, Mato JM, Rodes J: Effects of S-adenosylmethionine of lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol. 1996, 25: 200-205. 10.1016/S0168-8278(96)80074-2.PubMedView ArticleGoogle Scholar
- Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M: Stimulation of collagen α 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury. A link to tissue fibrosis?. Hepatology. 1994, 19: 1262-1271.PubMedGoogle Scholar
- Houglum K, Bedossa P, Chojkier M: TGF-α and collagen α 1(I) gene expression are increased in hepatic acinar zone I of rats with iron overload. Am J Physiol. 1994, 267: G908-G913.PubMedGoogle Scholar
- Niemela O, Parkkila S, Yla-Herttuala S, Villanueva J, Ruebner B, Halsted CH: Sequential acetaldehyde production, lipid peroxidation and fibrogenesis in micropig model of alcohol induced disease. Hepatology. 1995, 22: 1208-1214. 10.1016/0270-9139(95)90630-4.PubMedView ArticleGoogle Scholar
- Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM: Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995, 96: 620-630. 10.1172/JCI118077.PubMed CentralPubMedView ArticleGoogle Scholar
- Nanjii AA, Greenberg SS, Tahan SR, Fogt F, Loscalzo J, Sadrzadeh SM, Xie J, Stamler JS: Nitric oxide production in experimental alcoholic liver disease in the rat: role in protection from injury. Gastroenterology. 1995, 109: 899-907. 10.1016/0016-5085(95)90400-X.View ArticleGoogle Scholar
- Muriel P: Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol. 1998, 56: 773-779. 10.1016/S0006-2952(98)00220-2.PubMedView ArticleGoogle Scholar
- Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU: Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α 1(I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun. 1993, 194: 1044-1050. 10.1006/bbrc.1993.1927.PubMedView ArticleGoogle Scholar
- Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, Surrenti C: Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology. 1997, 25: 361-367. 10.1002/hep.510250218.PubMedView ArticleGoogle Scholar
- Maher JJ, Tzagarakis C, Gimenez A: Malondialdehyde stimulates collagen production by hepatic lipocytes only upon activation in primary culture. Alcohol Alcohol. 1994, 29: 605-610.PubMedGoogle Scholar
- Parola M, Pinzani M, Casini A, Leonarduzzi G, Marra F, Caligiuri A, Ceni E, Biondi P, Poli G, Dianzani MU: Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4-hydroxy-2,3-nonenal and other 4-hydroxy-2,3-alkenalks is related to their molecular structure. Biochem Biophys Res Commun. 1996, 222: 261-264. 10.1006/bbrc.1996.0732.PubMedView ArticleGoogle Scholar
- Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, Di Sario A, Salzano R, Ridolfi F, Saccomanno S, Jezequel AM, Benedetti A: Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology. 1998, 27: 720-726. 10.1002/hep.510270313.PubMedView ArticleGoogle Scholar
- Garcia-Trevijano E, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, Rojkind M: Trasforming growth factor β1 induces the expression of α (I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells. Hepatology. 1999, 29: 960-970. 10.1002/hep.510290346.PubMedView ArticleGoogle Scholar
- Nieto N, Friedman SL, Cederbaum AI: Cytochrome P502E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem. 2002, 277: 9853-9864. 10.1074/jbc.M110506200.PubMedView ArticleGoogle Scholar
- Nieto N, Cederbaum AI: Increased Sp1-dependent transactivation of the LAMã promoter in hepatic stellate cells co-cultured with HepG2 cells overexpressing cytochrome P450 2E1. J Biol Chem. 2003, 278: 15360-15372. 10.1074/jbc.M206790200.PubMedView ArticleGoogle Scholar
- Comporti M, Arezzini B, Signorini C, Sgherri C, Monaco B, Gardi C: F2-isoprostanes stimulate collagen synthesis in activated hepatic stellate cells: a link with liver fibrosis?. Lab Invest. 2005, 85: 1381-1391. 10.1038/labinvest.3700332.PubMedView ArticleGoogle Scholar
- Chen A, Davis BH: UV irradiation activates JNK and increases alpha (I) collagen gene expression in rat hepatic stellate cells. J Biol Chem. 1999, 274: 158-164. 10.1074/jbc.274.1.158.PubMedView ArticleGoogle Scholar
- Nieto N, Friedman SL, Greenwel P, Cederbaum AI: Cyp2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology. 1999, 30: 987-996. 10.1002/hep.510300433.PubMedView ArticleGoogle Scholar
- Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, Cederbaum AI: Ethanol and arachidonic acid increase α 2 (I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. J Biol Chem. 2000, 26: 20136-20145. 10.1074/jbc.M001422200.View ArticleGoogle Scholar
- De Bleser PJ, Xu G, Rombouts K, Rogiers V, Geerts A: Glutathione levels discriminate between oxidative stress and transforming growth factor-β signalling in activated rat hepatic stellate cells. J Biol Chem. 1999, 274: 33881-33887. 10.1074/jbc.274.48.33881.PubMedView ArticleGoogle Scholar
- Cao Q, Mak KM, Lieber CS: DLPC decreases TGFβ1 – induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2002, 28: G1051-G1061.View ArticleGoogle Scholar
- Nieto N: Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology. 2006, 44: 1487-1501. 10.1002/hep.21427.PubMedView ArticleGoogle Scholar
- Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M: Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology. 2000, 31: 109-116. 10.1002/hep.510310118.PubMedView ArticleGoogle Scholar
- Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, Ramirez F, Rojkind M: Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology. 2005, 42: 343-352. 10.1002/hep.20798.PubMed CentralPubMedView ArticleGoogle Scholar
- Chen A, Davis BH: The DNA binding protein BTEB mediates acetaldehyde-induced, Jun N-terminal kinase-dependent alphaI(I) collagen gene expression in rat hepatic stellate cells. Mol Cell Biol. 2000, 20: 2818-2826. 10.1128/MCB.20.8.2818-2826.2000.PubMed CentralPubMedView ArticleGoogle Scholar
- Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA: NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. Hepatology. 2004, 40: 263-265. 10.1002/hep.20296.View ArticleGoogle Scholar
- Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA: Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003, 285: G642-G651.PubMedView ArticleGoogle Scholar
- Bataller R, Sancho-Bru P, Ginès p, Lora JM, Al-Garawi A, Solè M, Colmenero J, Nicolàs JM, Jimènez W, Weich N, Gutièrrez-Ramos JC, Arroyo V, Rodès J: Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003, 125: 117-125. 10.1016/S0016-5085(03)00695-4.PubMedView ArticleGoogle Scholar
- Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998, 101: 890-898. 10.1172/JCI1112.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, Torok NJ: Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006, 43: 435-443. 10.1002/hep.21093.PubMedView ArticleGoogle Scholar
- Buck M, Kim DJ, Houglum K, Hassanein T, Chojkier M: C-Myb modulates transcription of the α-smooth muscle actin gene in activated hepatic stellate cells. Am J Physiol. 2000, 278: G321-G328.Google Scholar
- Nieto N, Friedman SL, Cederbaum AI: Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology. 2002, 35: 62-73. 10.1053/jhep.2002.30362.PubMedView ArticleGoogle Scholar
- Kawada N, Seki S, Inoue M, Kuroki T: Effect of antioxidants, resveratrol, quercetin and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology. 1998, 27: 1265-1274. 10.1002/hep.510270512.PubMedView ArticleGoogle Scholar
- Svegliati-Baroni G, Di Sario A, Casini A, Ferretti G, D'Ambrosio L, Ridolfi F, Bolognini L, Salzano R, Orlandi F, Benedetti A: The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol. 1999, 30: 868-875. 10.1016/S0168-8278(99)80141-X.PubMedView ArticleGoogle Scholar
- Reeves HL, Dach CL, Peak M, Burt AD, Day CP: Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol. 2000, 32: 465-472. 10.1016/S0168-8278(00)80398-0.PubMedView ArticleGoogle Scholar
- Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G: Inhibition of the Na+/H+ exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology. 2001, 120: 545-556. 10.1053/gast.2001.21203.PubMedView ArticleGoogle Scholar
- Kim YK, Rhim TY, Choi I, Kim SS: N-Acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem. 2001, 276: 40591-40598. 10.1074/jbc.M100975200.PubMedView ArticleGoogle Scholar
- Adachi T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K, Kawata S: NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology. 2005, 41: 1272-1281. 10.1002/hep.20719.PubMedView ArticleGoogle Scholar
- Robino G, Zamara E, Novo E, Dianzani MU, Parola M: 4-Hydroxy-2,3-alkenals as signal molecules modulating proliferative and adaptative cell responses. Biofactors. 2001, 15: 103-106.PubMedView ArticleGoogle Scholar
- Uchida K, Shiraichi M, Naito Y, Torii Y, Nakamura Y, Osawa T: Activation of stress signaling pathways by the end product of lipid peroxidation. 4-Hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem. 1999, 274: 2234-2242. 10.1074/jbc.274.4.2234.PubMedView ArticleGoogle Scholar
- Oleynyk JK, Khan NA, Ramm GA, Brown KE, O'Neill R, Britton RS, Bacon BR: Aldehydic products of lipid peroxidation do not directly activate rat hepatic stellate cells. J Gastroenterol Hepatol. 2002, 17: 785-790. 10.1046/j.1440-1746.2002.02798.x.View ArticleGoogle Scholar
- Whalen R, Rockey DC, Friedman SL, Boyer TD: Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Hepatology. 1999, 30: 927-933. 10.1002/hep.510300404.PubMedView ArticleGoogle Scholar
- Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A: Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology. 2005, 41: 1074-1084. 10.1002/hep.20683.PubMedView ArticleGoogle Scholar
- Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Tamagno E, Colombatto S, Marra F, Pinzani M, Parola M: Cytokine-induced migration of human hepatic stellate cells requires activation of c-Jun N-terminal kinase and intracellular generation of reactive oxygen species. Gut. 2007, 56: A62.Google Scholar
- Failli P, DeFranco R, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P, Pinzani M: Nitrovasodilators inhibit plateled derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology. 2000, 119: 479-492. 10.1053/gast.2000.9354.PubMedView ArticleGoogle Scholar
- Klassen LW, Tuma D, Sorrell MF: Immune mechanisms of alcohol-induced liver disease. Hepatology. 1995, 22: 355-357.PubMedGoogle Scholar
- Albano E: Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med. 2002, 32: 110-114. 10.1016/S0891-5849(01)00773-0.PubMedView ArticleGoogle Scholar
- Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E: Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med. 2002, 32: 38-45. 10.1016/S0891-5849(01)00757-2.PubMedView ArticleGoogle Scholar
- Thiele GM, Freeman TL, Klassen LW: mmunologic mechanisms of alcoholic liver injury. Semin Liver Dis. 2004, 24: I273-287. 10.1055/s-2004-832940.View ArticleGoogle Scholar
- Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, Bellomo G, Klassen LW, Thiele GM, Tuma DJ, Albano E: Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology. 2000, 31: 878-884. 10.1053/he.2000.5373.PubMedView ArticleGoogle Scholar
- Stewart SF, Vidali M, Day CP, Albano E, Jones DE: Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology. 2004, 39: 197-203. 10.1002/hep.20021.PubMedView ArticleGoogle Scholar
- Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP: Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005, 54: 987-993. 10.1136/gut.2004.057968.PubMed CentralPubMedView ArticleGoogle Scholar
- Rigamonti C, Mottaran E, Reale E, Rolla R, Cipriani V, Capelli F, Boldorini R, Vidali M, Sartori M, Albano E: Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology. 2003, 38: 42-49. 10.1053/jhep.2003.50275.PubMedView ArticleGoogle Scholar
- Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, Badeaux J, Albano E, Ingelman-Sundberg M, Badger TM: Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp Biol Med. 2008, 233: 344-355. 10.3181/0707-RM-203.View ArticleGoogle Scholar
- Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006, 6: 772-783. 10.1038/nri1937.PubMedView ArticleGoogle Scholar
- Racanelli V, Rehermann B: The liver as an immunological organ. Hepatology. 2006, 43: S54-62. 10.1002/hep.21060.PubMedView ArticleGoogle Scholar
- Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH: Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity. 2007, 26: 117-129. 10.1016/j.immuni.2006.11.011.PubMedView ArticleGoogle Scholar
- Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, Blessing M, Schmitt E, Lohse AW: MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology. 2003, 37: 1079-1085. 10.1053/jhep.2003.50191.PubMedView ArticleGoogle Scholar
- Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z: A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology. 2007, 46: 1519-1529. 10.1002/hep.21823.PubMedView ArticleGoogle Scholar
- Pinzani M, Rombouts K, Colagrande S: Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005, 42 (Suppl 1): S22-36. 10.1016/j.jhep.2004.12.008.PubMedView ArticleGoogle Scholar
- Chang CY, Argo CK, Al-Osaimi AMS, Caldwell SH: Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol. 2006, 40 (Suppl 1): S51-60.PubMedGoogle Scholar
- de Alwis NMW, Day CP: Non-alcoholic fatty liver: the mist gradually clear. J Hepatol. 2008, 48 (Suppl 1): S105-112.Google Scholar
- Williams RJ, Spencer JP, Rice-Evans C: Flavonoids: antioxidants or signalling molecules?. Free Radic Biol Med. 2004, 36: 838-849. 10.1016/j.freeradbiomed.2004.01.001.PubMedView ArticleGoogle Scholar
- Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, Thurman RG: Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther. 2002, 9: 183-191. 10.1038/sj.gt.3301638.PubMedView ArticleGoogle Scholar
- Okuyama H, Nakamura H, Shimahara Y, Uyama N, Kwon YW, Kawada N, Yamaoka Y, Yodoi J: Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol. 2005, 42: 117-123. 10.1016/j.jhep.2004.09.020.PubMedView ArticleGoogle Scholar
- Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST: rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology. 2005, 42: 335-342. 10.1002/hep.20803.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.